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ABSTRACT 
Staphylococcus aureus is a gram-positive, extracellular bacterium that has emerged as an 
important human pathogen. This bacterium is a leading cause of skin and soft tissue infections 
(SSTIs) in humans, often leading to invasive and life-threatening infections. Treatment of S. 
aureus infections is becoming more complicated due to the rise of methicillin-resistant S. aureus 
(MRSA) strains, which are becoming increasingly resistant to a number of antibiotics. In the 
United States, invasive MRSA infections result in more deaths annually than any other infectious 
agent. 
Despite a dire need, there is currently no vaccine against S. aureus infections. The failure 
of past vaccine candidates may be due to a lack of understanding of immune correlates of 
protection and how to obtain them through vaccination. Additionally, attempts to develop 
vaccines have, up to this point, focused solely on eliciting high titer antibody responses to 
antigens. Accumulating evidence from human patients and in vivo studies suggest that CD4+ T 
cells are important mediators of protection from S. aureus infections.  
TH17 cells, and their namesake cytokine IL-17, are involved in protection against 
cutaneous infections. TH17 cells and IL-17 are important for neutrophil recruitment to sites of 
infection, which is required for clearance of S. aureus, as well as antimicrobial peptide (AMP) 
production from epithelial cells. Therefore, a protective vaccine will likely require a strong TH17 
response to S. aureus antigen. Data also implicates TH1 cells and the associated cytokine IFNγ as 
important mediators of protection against S. aureus, especially during invasive infection. Based 
 ix 
on these data, the most effective vaccine will likely be one that can elicit strong TH17 and TH1 
responses against vaccine antigens. 
My goal was to develop an adenovirus (Ad) vector based vaccine that could provide 
protection from cutaneous MRSA infections. Ad is an attractive vaccine vector due to its potent 
T cell adjuvant capabilities and high level and duration of transgene expression. As T cells have 
been shown to be important for immunity to S. aureus, I hypothesized that Ad vectors expressing 
domains from MRSA surface proteins as transgenes would elicit more potent T cell responses to 
these antigens than protein immunization and would provide protection from cutaneous 
infection. I generated Ad vectors expressing MRSA antigens and assessed the immune response 
induced by vaccination. I also assessed the ability of these Ad vectors to provide protection 
against MRSA infection using a mouse model of cutaneous infection.  
 1 
 CHAPTER ONE 
INTRODUCTION 
Staphylococcus aureus 
 Staphylococcus aureus is a gram positive, cocci shaped extracellular bacterium. It is 
transmitted mainly through direct skin to skin contact, however transmission from fomites can 
also occur (Desai et al. 2011). While it is typically a commensal bacterium present on the skin 
and mucous membranes of healthy individuals, S. aureus has the potential to cause superficial 
and invasive infections that can be life threatening. It is estimated that S. aureus colonizes the 
nares of more than 30% of the human population (Krismer et al. 2017). Certain populations, 
including health care workers, hospitalized patients, and needle users have increased 
colonization rates. Importantly, nasal carriers of S. aureus have a higher risk of bloodstream 
infection, and these infections are typically caused by the colonizing strain.  
 While S. aureus does not normally cause infection in healthy skin it can cause serious 
infections following skin damage, or if allowed to enter the bloodstream. In this way, commensal 
bacteria can become pathogenic following tissue damage. S. aureus is the leading cause of skin 
and soft tissue infections (SSTIs) which include impetigo, cellulitis, subcutaneous abscesses, and 
infected ulcers and wounds. These SSTIs are the greatest contributors to S. aureus morbidity and 
are often chronic and frequently recurrent (Brown et al. 2014).  Furthermore, SSTIs may lead to 
invasive, life-threatening infections.  
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In addition to SSTIs, S. aureus can cause invasive infections including bacteremia, 
abscesses, pneumonia, meningitis, endocarditis and sepsis. These invasive infections are 
associated with significant morbidity and mortality, contributing to more deaths annually in the 
United States than HIV/AIDS, viral hepatitis, and influenza combined  (Boucher and Corey 
2008). Treatment of these infections has become complicated due to the emergence of 
methicillin-resistant S. aureus (MRSA) strains, which are becoming resistant to a growing 
number of antibiotics.  
 The defining characteristic of MRSA is the presence of the staphylococcal cassette 
chromosome (SCC) mec, a mobile genetic element (MGE) that confers broad spectrum beta-
lactam resistance (Ito et al. 2014). MRSA strains can be divided into either hospital associated 
(HA) or community associated (CA) strains. These two groups tend to present different clinical 
features and have differing susceptibility to antibiotics. Hospital associated (HA) MRSA strains 
cause infections in hospitalized patients and are a leading cause of hospital acquired infections 
worldwide. Community associated (CA) MRSA stains cause infection of otherwise healthy 
individuals. The USA300 strain is the most prevalent CA-MRSA strain in the United States and 
is commonly associated with skin and soft tissue infections (DeLeo et al. 2010).  
 In addition to antibiotic resistance, S. aureus pathogenesis depends on a number of 
enzymes, toxins and surface proteins, many of which are encoded for on MGEs. Secreted 
enzymes such as coagulase, staphylokinase, and proteases help the bacteria evade host defenses 
and invade new tissues. During infection S. aureus also secretes hemolysins and leukotoxins. 
These toxins lyse red and white blood cells, respectively, by forming pores in the cell membrane 
leading to necrotic cell death (Kong, Neoh, and Nathan 2016). S. aureus enterotoxins, including 
toxic shock syndrome toxin 1 (TSST-1), are superantigens that non-specifically bind to MHCII 
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and stimulate T cell activation and proliferation. As a result, these toxins interfere with intestinal 
functioning, causing vomiting and diarrhea (Otto 2014). Some S. aureus strains also produce 
serine proteases, known as exfoliative toxins, that cause detachment of the epidermis leading to 
blistering of the skin and secondary infections (Kong, Neoh, and Nathan 2016). 
 S. aureus surface adhesion proteins are important virulence factors that facilitate 
adhesion, tissue invasion and evasion of host defenses. Adherence to the extracellular matrix 
(ECM) and host cells is mainly mediated by proteins known as microbial surface components 
recognizing adhesive matrix molecules (MSCRAMM). The defining feature of these proteins are 
multiple IgG-like folded domains within the ligand binding region. MSCRAMM proteins are 
anchored to the cell wall peptidoglycan by a peptidoglycan binding motif (LPXTG) as well as 
wall and membrane spanning regions on their C-terminal end. The N-terminal portion contains 
the signal sequence and the ligand binding region. (Foster and Hook 1998) 
  The MSCRAMM family consists of clumping factor (Clf) and serine-aspartate repeat 
(Sdr) proteins, fibronectin-binding proteins (FnBPs), and collagen adhesin (Cna) proteins. ClfA, 
the archetypal MSCRAMM protein, binds fibrinogen which then mediates attachment to host 
cells through its interaction with αv3 integrins (McDonnell et al. 2016). Alternatively, ClfA 
can use self-secreted von Willebrand factor binding protein to adhere to host cells (Claes et al. 
2017). These interactions allow for S. aureus adhesion to endothelial cells, an important step in 
the development of S. aureus associated endocarditis (Josse, Laurent, and Diot 2017). During 
sepsis fibrinogen binding induces platelet aggregation, abscess formation and the development of 
thromboembolic lesions (McAdow et al. 2011). 
Other representative MSCRAMM proteins include SdrD and FnBPA. SdrD binds to 
Desmoglein 1 on keratinocytes and nasal epithelial cells (Josse, Laurent, and Diot 2017). SdrD is 
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important for nasal colonization and has been shown to support bacterial survival in vivo 
(Askarian et al. 2016). Fibronectin binding proteins (FnBP), including FnBPA, promote adhesion 
to the ECM and invasion of new tissues by binding fibronectin. Fibronectin acts to form a bridge 
between bacteria and host cells through its interaction with α51 integrins (Fowler et al. 2003). 
FnBP-Fibronectin- α51 integrin interactions can also induce internalization of the bacteria 
through the FAK-Src pathway (Josse, Laurent, and Diot 2017). Internalization may support 
infection by promoting bacterial dissemination and by shielding S. aureus from detection by the 
immune system.  
The MSCRAMM proteins ClfA and SdrE both contribute to immune evasion by 
suppressing complement activation. ClfA binds complement regulator factor I (fI) which cleaves 
the complement protein C3b into its inactive form, leading to decreased phagocytosis of the 
bacteria (Hair et al. 2010).  In a similar manner, SdrE binds to factor H (fH) which acts as a 
cofactor for fI and also accelerates the decay of the alternative complement pathway C3 
convertase, C3bBb (Sharp et al. 2012). SdrE mediated suppression of complement results in 
reduced bacterial killing by PMNs, thus promoting infection.  
Immune Response to S. aureus Infection 
 Innate immune sensing of bacterial components is a critical first step in mounting an 
immune response to S. aureus. Initial innate responses to bacterial components induce the 
production of proinflammatory cytokines and chemokines including TNF-α, IL-1, IL-12, IL-8, 
GM-CSF, CCL2, and CCL3 (Fournier and Philpott 2005). These proinflammatory factors are 
produced by cells of the innate immune system, as well as epithelial and endothelial cells. The 
induction of rapid inflammatory responses by epithelial cells is particularly important, as 
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invasive S. aureus infections (including sepsis) often develop from skin and soft tissue 
infections.  
During infection lipopeptides, including lipoteichoic acid (LTA), present on the surface 
of extracellular bacterial are recognized by heterodimers of TLR2 and TLR1 or TLR6 (Krishna 
and Miller 2012). These interactions, along with engagement of co-receptors CD14 and CD36, 
activate signaling through MYD88 which leads to activation of NFκB and the production of 
proinflammatory cytokines and chemokines (Krishna and Miller 2012). Following internalization 
of S. aureus or release of bacterial components from the phagolysosome the intracellular sensor 
NOD2 senses muramyl dipeptide, a breakdown product of S. aureus peptidoglycan. NOD2 
signaling further activates NFκB dependent expression of proinflammatory cytokines and 
chemokines, including pro-IL-1. Pore formation, caused by hemolysins or activation of the 
purinergic receptor P2X7, or phagosome rupture allow for muramyl dipeptide mediated 
activation of the NLRP3 inflammasome. The NLRP3 inflammasome is then able to cleave pro-
IL-1 into its mature form (Munoz-Planillo et al. 2009).  
 In addition to TLR and NLR recognition of pathogen associated molecular patterns 
(PAMPs), it has also been shown that S. aureus protein A binds to TNF-α receptor 1 (TNFR1) on 
innate immune cells and epithelial cells. This interaction induces activation of NFκB and 
downstream production of proinflammatory cytokines including IL-8, as well as recruitment of 
PMNs (Gomez et al. 2004). Additionally, keratinocytes contain pre-made stores of IL-1α that are 
released in response to tissue damage and infection. Both IL-1α and IL-1 bind to the IL-1R and 
induce production of neutrophil attracting chemokines such as CXCL1, CXCL2, and CXCL8 
(Olaru and Jensen 2010). 
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 Neutrophils are rapidly recruited to sites of S. aureus infection and are an essential part of 
the host defense against this pathogen. This is evidenced by the fact that patients with defects in 
neutrophil number or function (e.g. congenital neutropenia or myeloperoxidase deficiency) have 
increased susceptibility to S. aureus infections (Andrews and Sullivan 2003; Lakshman and Finn 
2001). Recognition of bacterial PAMPs by pattern recognition receptors (PRRs) leads to 
increased expression of adhesion molecules on neutrophils and endothelial cells, as well as 
production of neutrophil attracting chemokines, which facilitate neutrophil diapedesis and entry 
into infected tissue (Ley et al. 2007). Once recruited to the sites of infection, neutrophils help to 
control infection though the formation of abscesses. Upon encountering S. aureus within 
abscesses neutrophils use a variety of mechanisms to mediate bacterial killing.   
 Following engagement of Fc or complement receptors neutrophils phagocytose 
opsonized bacteria. Inside the phagosome oxidative burst generates reactive oxygen species 
which can kill bacteria. Furthermore, antimicrobial peptides, proteinases, and acid hydrolases 
present within the phagosome have direct antimicrobial effects. Neutrophils also release 
neutrophil extracellular traps (NETs), containing antimicrobial peptides and proteases, that trap 
and kill extracellular bacteria (Pilsczek et al. 2010).  
 Accumulating evidence suggests that macrophages play an important role in the immune 
response to S. aureus infections, and that M1 macrophages are particularly important for 
bacterial clearance (Accarias et al. 2015; Pozzi et al. 2015). In mice a predominately M2 
response is associated with greater susceptibility to S. aureus infection whereas inoculation with 
M1 cells rescues abscess formation and helps prevent bacterial spread (Pozzi et al. 2015). In 
contrast to the anti-inflammatory M2 macrophage subset, M1 macrophages secrete 
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proinflammatory cytokines that recruit neutrophils, activate antimicrobial mechanisms and 
promote polarization of TH1 and TH17 cells.  
 Bacterial proteins located in the cytoplasm or phagosomal compartments of antigen 
presenting cells (APCs) can be processed and presented to naïve T cells via MHCII, inducing 
differentiation into effector and memory T cell populations. Both mouse and human studies have 
shown that effector and memory T cells are induced by S. aureus, particularly TH1 and TH17 
subsets (Broker, Mrochen, and Peton 2016). Furthermore, the susceptibility of patients with 
TH17 or other CD4+ T cell deficiencies to S. aureus infections highlights the importance of these 
cell types in the immune response against this pathogen. In addition to CD4+ T cells, memory 
CD8+ and γδ T cell subsets are induced by S. aureus infection (Broker, Mrochen, and Peton 
2016; Murphy et al. 2014).  
 In models of systemic infection TH1 produced IFNγ has been shown to promote 
neutrophil recruitment and provide protection against S. aureus infection by enhancing the 
activation and bactericidal activities of phagocytic cells (Krishna and Miller 2012). Additionally, 
in mouse models of systemic infection IFNγ production from TH1 cells was shown to be required 
for vaccine mediated protection (Lin et al. 2009). While TH1 cells are thought to be important for 
protection against sepsis, data suggests that IL-17 and TH17 cells also play an important role in 
defending against S. aureus infections, particularly during cutaneous infections.  
TH17, as well as  T cells, natural killer (NK), and NKT cells produce IL-17 which 
binds to keratinocytes and innate immune cells to induce expression of granulopoiesis factors 
and chemokines. These molecules promote maturation and recruitment of neutrophils to the sites 
of infection. IL-17 also induces neutrophil and keratinocyte production of antimicrobial peptides 
(AMPs), which have bactericidal activities that are important for clearance of infection. Along 
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with IL-17, TH17 and γδ T cells also produce IL-22. IL-22 activates keratinocytes to produce 
AMPs and proliferate, playing an important role in bacterial clearance and wound healing during 
infection. (Figure 1) 
T cells also support B cell activation and IgG class switching during infection, as 
evidenced by the fact that immune-competent individuals generate high titers of class switched 
anti-S. aureus antibodies during infection (Broker, Holtfreter, and Bekeredjian-Ding 2014; 
Kolata et al. 2011). The majority of anti-S. aureus antibodies generated during human infections 
are directed against toxins and cell surface components. During infection, these antibodies can 
bind to S. aureus toxins and prevent their harmful effects. Additionally, antibody binding to the 
bacterial surface allows for the opsonization of bacteria by phagocytic cells or activation of the 
classical complement pathway. Unfortunately, S. aureus has evolved a number of mechanisms to 
evade the host antibody response and therefore the generation of S. aureus specific antibodies 
does not reliably provide protection against infection. It should be noted that while an antibody 
response may not be sufficient to prevent infection, several studies have shown the importance of 
anti-toxin antibodies in limiting disease severity and tissue damage (Broker, Holtfreter, and 
Bekeredjian-Ding 2014).  
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Figure 1. The Cutaneous Immune Response Against S. aureus. During cutaneous S. aureus 
infection, bacterial components activate TLR2 and other PRRs on keratinocytes and APCs in the 
epidermis and dermis. This activation leads to the production of cytokines such as IL-1α, IL-1, 
IL-6 and IL-23, which stimulate the production of IL-17 by TH17 cells, γδ T cells, NK cells, and 
NKT cells. IL-17 binds to IL-17 receptors (IL-17R) on keratinocytes and innate immune cells to 
induce expression of CCL20, granulopoesis factors (G-CSF and GM-CSF) and chemokines such 
as CXCL1, CXCL2, CXCL5, and CXCL8, which promote maturation and recruitment of 
neutrophils and TH17 cells. Once recruited to the site of infection, neutrophils phagocytose 
opsonized bacteria and mediate bacterial killing. Additionally, IL-17 and IL-22 induce the 
production of AMPs from keratinocytes and neutrophils which mediate bacterial killing. IL-22 
also induces keratinocyte proliferation and is therefore important in wound healing during 
infection. Taken from (Miller and Cho 2011).  
 
Current S. aureus Vaccine Approaches 
 Due to the severe morbidity and mortality associated with S. aureus infections, and the 
rise of antibiotic resistance strains, developing a vaccine against S. aureus is of the utmost 
importance. To date several vaccine candidates have been developed, however none have 
demonstrated efficacy in late stage clinical trials (Giersing et al. 2016). Ideally, a vaccine would 
provide sterilizing protection from S. aureus however that may be an overly ambitious goal. A 
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more realistic goal would be to develop a vaccine that can reduce the severity of infection, which 
would significantly reduce the mortality and cost associated with S. aureus infections. While 
prior infection does not provide protection against recurrent S. aureus infection, human carriers 
do tend to develop less severe infections than noncarriers which suggests that carriers are able to 
develop some immunity to S. aureus (Giersing et al. 2016).  
 Several challenges have hindered the development of an effective S. aureus vaccine to 
date. Compared to other bacteria for which vaccines have been developed, S. aureus is a 
commensal organism in humans and therefore has evolved numerous defenses and evasion 
strategies against the host immune response in order to maintain persistent colonization. 
Antigenic variation between strains, as well as the numerous invasion and colonization 
mechanisms used by the bacteria have also made it challenging to create an effective vaccine. 
Finally, a lack of understanding of correlates of protection have impeded the development of 
vaccines that induce protective immunity. 
 In the past, S. aureus immunization strategies have been aimed at generating high titers of 
antibodies against a single surface antigen or virulence factor (Proctor 2015). While this strategy 
has proven effective for vaccines against other bacteria it has not been effective for S. aureus, 
likely due to the many redundant virulence factors and surface proteins encoded by the bacteria. 
Two subunit vaccines, StaphVAX and V710, underwent phase III testing but neither showed 
consistent efficacy in humans. StaphVAX, a polysaccharide and protein-conjugated vaccine 
directed against two S. aureus capsular polysaccharides (CP), failed to provide protection from 
bacteremia in hemodialysis patients (Fattom et al. 2015). A phase III clinical trial for the subunit 
vaccine candidate V710, which directs an immune response against the cell-wall anchored iron 
scavenger protein IsdB, was terminated when it was discovered that vaccination induced 
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significantly greater mortality and other adverse events compared to the placebo (Fowler et al. 
2013). 
 Analysis of the failed efficacy trails led researchers to hypothesize that a multi-antigen 
approach targeting virulence factors, toxins and adhesion proteins would prove more effective. 
The most notable candidate is Pfizer’s SA4Ag vaccine, composed of CP5, CP8, and recombinant 
ClfA and manganese transporter MntC. Results from phase I studies have shown that vaccination 
induces high titers of functional antibodies against vaccine antigens (determined by 
opsonophagocytic activity assays) (Frenck et al. 2017). A phase II study is currently underway to 
evaluate the safety and efficacy of the vaccine in patients undergoing spinal fusion surgery. A 
number of other multi-antigen subunit vaccine candidates are being evaluated in pre-clinical 
trials (Giersing et al. 2016). Additionally, two monoclonal antibody based (mAb) vaccine 
candidates are currently undergoing clinical trials, however previous studies using mAb have not 
shown efficacy in humans (Bagnoli 2017; Ruzin et al. 2018).  
 All vaccine candidates to date have been designed to generate an antibody response 
against S. aureus antigens, however there is a growing consensus that T-cell immunity is 
important for vaccine mediated protection. Observations from individuals with deficiencies in 
humoral immunity, such as agammaglobulinemia, show that they are not at increased risk for S. 
aureus infections (Proctor 2012). In contrast, patients with TH17 cell or neutrophil deficiencies 
are more prone to S. aureus infections. Individuals with CD4+ T cell deficiencies (such as 
HIV/AIDS patients) or individuals with defective IFNγ production are also more susceptible to 
infection, highlighting the importance of cell mediated immunity in protection.  
These observations support recent findings from animal studies that show TH17 and other 
T cell subsets are important mediators of protection against S. aureus infection. TH17 cells 
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produce IL-17, which has been shown to be critical for protecting mice and humans from S. 
aureus skin infections (Cho et al. 2010; Puel et al. 2011). Mice with defects in either TH17 cells 
or IL-17 production are more susceptible to S. aureus, and both have been shown to be required 
for vaccine mediated protection in mouse models (Lin et al. 2009). The same study showed that 
TH1 cells and TH1 produced IFNγ were also required for vaccine mediated protection. S. aureus 
infections in IL-17 receptor or γδ T cell deficient mice are more severe, with deficient mice 
exhibiting larger abscess sizes and increased bacterial burden in the wound (Fischer 2008). 
Given that γδ T cells are a major producer of IL-17 in the skin, these findings further highlight 
the importance of IL-17 signaling in immunity against S. aureus.  
Mounting evidence points to T cells and cell mediated immunity as the mediators of 
protection against S. aureus infections, therefore a successful vaccine will likely need to induce 
potent T cell responses to vaccine antigens. Recently the vaccine candidate NDV-3 has been 
shown to induce protective TH17 and TH1 responses against S. aureus. NDV-3 is composed of 
the recombinant Als3 antigen from Candida albicans, which shares structural similarity with S. 
aureus clumping factors, formulated with alum in PBS. NDV-3 was shown to provide protection 
against sepsis in mice and has completed phase I clinical trials demonstrating safety and 
tolerability in humans (Yeaman et al. 2014). While this vaccine candidate holds promise, it is 
formulated with Alum which characteristically induces a predominantly TH2 response. Given the 
importance of TH17 and TH1 cells in vaccine mediated protection, different adjuvant strategies 
that more potently induce these T cell subsets may be more effective and should be considered 
for future vaccine development.  
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Vaccines and Common Adjuvants 
 Vaccines represent one of the single greatest public health measures in human history. It 
is estimated that vaccines prevent almost 6 million deaths annually (Andre et al. 2008). Targeted 
vaccination strategies have led to the eradication of smallpox and rinderpest, and diseases such 
as polio and measles are close to eradication (Gardner et al. 2018; Orenstein et al. 2018; 
Simonsen and Snowden 2018). Despite the past success of vaccines, there is still much work to 
be done in creating effective vaccines against HIV, malaria, S. aureus, and other pathogens. 
 Vaccines work by providing an initial, controlled, exposure to an infectious agent. This 
allows the host immune system to develop a protective immune response against the pathogen. 
The development of a protective immune response ultimately depends on the creation of 
effective adaptive immune responses, which provide immunological memory after the initial 
exposure. Traditional vaccine approaches have utilized either live attenuated or killed versions of 
the pathogen. The advent of molecular biology and recombinant DNA technology has allowed 
for the development of subunit vaccines, which involve immunization with a component of the 
disease-causing agent rather than the pathogen itself. Subunit vaccines are considered to be safer 
than vaccines using live attenuated pathogens because they eliminate the risk of reversion 
(Moyle and Toth 2013). A major problem with subunit vaccines is that they are not as 
immunostimulatory as live attenuated or killed versions, and therefore require the use of an 
adjuvant to elicit a robust and effective immune response (Purcell, McCluskey, and Rossjohn 
2007). 
An adjuvant is something that is administered as part of a vaccine in order to enhance the 
immunogenicity of the vaccine. Adjuvant types include insoluble salts, emulsion based 
adjuvants, and PAMPs. Aluminum salts, or Alum, was the first identified adjuvant and is 
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currently used in a number of vaccines, including the diphtheria and tetanus toxins and pertussis 
vaccine and vaccines for hepatitis A and B (McKee and Marrack 2017). The adjuvant effects of 
Alum are characterized by a TH2 and T follicular helper (TFH) cell response and a predominantly 
IgG1 isotype response (McKee and Marrack 2017).  
 Alum binds to protein antigen and increases it’s stability and retention at injection sites, 
facilitating a slow release of the antigen (Oleszycka and Lavelle 2014). In addition, alum 
increases activation of APCs which then present antigen to TH cells in the draining lymph nodes 
(dLNs) (Kool et al. 2008). These activated TH cells are then able to support B cell activation 
leading to high antibody titers against the vaccine antigen. Interactions between alum and lipids 
on the membrane of dendritic cells (DCs), as well as alum induced release of uric acid crystals 
and dsDNA, have been shown to induce signaling via the Syk-PI3 kinase pathway (Kool et al. 
2008; Marichal et al. 2011). Activation of the Syk-PI3 kinase pathway promotes a TH2 response, 
while inhibiting IL-12 production and a TH1 response (Mori et al. 2012). Alum has also been 
shown to activate the NLRP3 inflammasome, however there is conflicting data regarding the role 
of this activation in the adjuvanticity of alum.  
 The first emulsion based adjuvant, Freund’s Complete Adjuvant (FCA) was developed in 
the 1930s. FCA consists of a water-in mineral oil emulsion containing Mycobacterium 
tuberculosis. Despite its ability to generate strong antibody and cellular immune responses FCA 
is not approved for use in humans due to its propensity to cause necrotic abscesses. Incomplete 
Freund’s Adjuvant, which lacks Mycobacterium tuberculosis, has been used in vaccine 
development and has been shown to enhance cellular immunity and generate enhanced 
IgG1/IgG2a antibody responses (Shibaki and Katz 2002). Squalene based emulsions, such as 
MF59 and AS03, are currently approved for use in humans and induce both humoral and cellular 
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immune responses. It is thought that cell injury and damage signals induced by squalene based 
adjuvants activate innate sensors leading to MyD-88 activation (Vono et al. 2013). 
 As scientists have gained increased understanding of the immune response to various 
PAMPs the use of PAMPs as adjuvants has allowed for the development of more efficient and 
effective vaccines.  PAMPs that have been utilized as adjuvants include monophosphoryl lipid A 
(a derivative of LPS) and the synthetic TLR4 agonist glucopyranosyl lipid A (Pantel et al. 2012; 
Thompson et al. 2005). Unmethylated CpG motifs and small molecule TLR7/8 agonists are also 
being investigated as potential vaccine adjuvants due to their ability to activate TL9 or TLR7/8, 
respectively (Scheiermann and Klinman 2014; Smith et al. 2016). 
  Another PAMP that is being increasingly used as an adjuvant is flagellin. Flagellin 
(FliC) is a component of the bacterial protein flagellum. FliC is an ideal adjuvant because it 
potently activates both the innate and adaptive arms of immunity. Furthermore, the plasticity of 
flagellin allows for the insertion of peptide sequences to create fusion proteins of FliC and 
vaccine antigens. The adjuvant effects of FliC are observed both when it is coadministered with 
vaccine antigens and when it is used to create fusion proteins.  
One mechanism through which FliC activates the immune response is through TLR5 
signaling. The N and C terminal domains of FliC are recognized by TLR5 leading to activation 
of NFκB (MyD88 dependent) and IRF3 (MyD88 independent) (Lu and Sun 2012; Mizel et al. 
2003; Vijay-Kumar et al. 2008). NFκB activation leads to the production of proinflammatory 
cytokines, additionally IRF3 activation leads to production of IFN-. In addition to activating 
TLR5, the 35 C-terminal amino acids of FliC activate the NLRC4 inflammasome, resulting in 
the cleave of pro-IL-1 and pro-IL-18 into their mature form which can then be secreted from 
the cell (Lightfield et al. 2008; Miao et al. 2006). In vitro studies have shown that administration 
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of flagellin or flagellin-based vaccines increase antigen accumulation in the dLN and activation 
of DCs, T cells and B cells (Mizel and Bates 2010). Flagellin also promotes class switching in B 
cells (Bennett et al. 2015).  
Viral vectors have also been used as adjuvants in vaccine development. Adenovirus 
vectors have been used as vaccine vectors due to their ability to potently activate both innate and 
adaptive immune responses. In addition, these vectors are capable of carrying large transgenes 
and can also displaying antigen on the viral capsid. Adenoviruses and their use as vaccine 
vectors will be discussed in the following sections. 
Adenovirus 
Adenoviruses (family Adenoviridae) are non-enveloped viruses whose genome consists 
of a 34-43kb linear segment of double stranded DNA. Currently, over 60 different types of 
human adenoviruses (Ad) have been identified and are grouped into species A-G (Jones et al. 
2007). Traditionally human Ads have been grouped into species based on hemagglutination and 
serum neutralization, however more recently identified virus types (52-68) have been grouped 
based on genomic sequencing (Ghebremedhin 2014; Huang and Xu 2013). Adenovirus type 5 
(Ad5), belonging to species C, was the focus of our experiments. In humans Ad causes a variety 
of respiratory, ocular and gastrointestinal infections. These infections, affecting mainly children, 
are typically self-limiting however more severe and even fatal infections can occur in 
immunocompromised patients (Bruno et al. 2003; Hoffman 2006).   
 The icosahedral viral capsid is ~90nm in diameter and consists primarily of 240 trimers 
of the hexon protein. At each of the capsids five-fold apices a penton base anchors a trimer of 
fiber proteins to the capsid. The outer surface of the capsid is also decorated with pIX, which 
helps to stabilize the viral capsid. Other minor proteins, including pIIIa, pVI and pVIII are also 
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associated with the capsid.  The interior of the capsid contains the virion protease, the dsDNA 
molecule and five other polypeptides that are associated with the viral DNA (Figure 2).  
 Initiation of infection begins with binding of the fiber knob domain to a cellular receptor, 
typically the Coxsackie and Adenovirus receptor (CAR) or CD46 (Bergelson et al. 1997; 
Gaggar, Shayakhmetov, and Lieber 2003). Following initial binding to the cellular receptor,  
secondary interactions between the penton base and αv integrins facilitate internalization of the 
virus via clathrin-mediated endocytosis (Wickham et al. 1993). Following endocytosis partial 
disassembly of the capsid occurs as capsid proteins including penton base, fiber and pIIIa are 
released into the acidified endosome. This partial disassembly allows pVI to be released into the 
endosome where it induces endosomal lysis and allows for escape of the virus into the cytoplasm 
(Maier et al. 2010; Wiethoff et al. 2005). 
Upon release into the cytoplasm, viral particles associate with microtubule motors and 
traffic along microtubules to the nucleus (Bremner et al. 2009). At the nucleus the partially 
uncoated virions dock at the nuclear pore complex (NPC) and the viral genome is released into 
the nucleus where replication occurs (Trotman et al. 2001). Replication of the viral genome is 
divided into two stages, early phase and late phase. Early genes encode for proteins involved in 
regulating expression of viral or host genes required for viral DNA replication, as well as genes 
involved in preventing premature cell death. Late phase genes encode for structural proteins and 
proteins involved in capsid assembly. Following DNA replication and capsid assembly the newly 
formed virions are released from the cell via virally induced cell lysis. 
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Figure 2. Diagram of the Adenovirus Capsid. The viral capsid is comprised mainly of hexon 
protein. At each vertex of the capsid a penton base anchors the fiber protein to the capsid. The 
minor proteins IIIa, VI, VIII, and IX make up the remainder of the capsid structure. The vial 
protease (not shown) and dsDNA molecule reside within the capsid. The core proteins V, VII, 
Mu, Terminal protein, and IVa2 (not shown) are associated with the viral DNA. Taken from 
(Thaci et al. 2011). 
 
Innate Immune Response to Adenovirus 
 Upon infection Adenovirus is able to rapidly and potently activate the immune system, 
making Adenovirus an attractive vaccine vector. Innate sensing of Ad infection triggers the 
release of cytokines such as IL-6, TNF-α, and IL-1 into the bloodstream, creating a 
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proinflammatory state (Mistchenko et al. 1994). This proinflammatory state is important for the 
recruitment of cytotoxic immune cells to the sites of infection. In addition, virally infected cells 
produce type 1 interferons which induce an antiviral state in neighboring cells (Randall and 
Goodbourn 2008).  The initial innate immune response to Ad is also important for inducing a 
robust adaptive immune response. 
 Adenovirus in the bloodstream can interact with a variety of factors including 
components of the complement system as well as IgG and IgM antibodies. Both the classical and 
alternative complement pathways seem be involved in Ad induced complement activation (Tian 
et al. 2009). Naturally occurring IgM, as well as pre-existing IgG antibodies bound to Ad are 
able to mediate viral opsonization via the classical complement pathway (Cichon et al. 2001). In 
addition, complement protein C3 has been shown to directly bind to the Ad capsid, activating the 
alternative complement pathway (Jiang et al. 2004). Complement activation leads to a proteolytic 
cleavage cascade that results in the formation of the membrane attack complex, creating pores in 
the membrane and killing the cell or pathogen. In the liver IgM has been shown to mediate Ad 
clearance by Kupffer cells (Khare et al. 2013), however binding of coagulation factor X (FX) to 
Ad allows the virus to evade this complement mediated clearance (Xu et al. 2013). 
 The primary inflammatory response to Ad comes from tissue resident macrophages 
including alveolar macrophages and Kupffer cells. Cellular pattern recognition receptors (PRRs) 
detect viral components and rapidly induce expression of various cytokines and chemokines. 
Within 30 minutes following Ad infection alveolar macrophages express mRNA for 
proinflammatory cytokines TNF-α, IL-12, and IL-6 (Zsengeller et al. 2000). Similarly it has been 
shown that marginal zone macrophages begin transcribing IL-1α, IL-I, TNF-α, and CXCL2 
within 30 minutes following Ad infection (Di Paolo et al. 2009). The expression of these genes 
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was shown to be induced independent of TLR9 or IFN-IR signaling. This same study found that 
binding of Ad penton base to integrins present on the cell surface leads to expression of IL-1α 
and subsequent signaling through the IL-1R1 (Di Paolo et al. 2009). This signaling activates 
expression of polymorphonuclear (PMN) leukocyte chemokines CXCL1 and CXCL2 which are 
important for recruiting PMNs, such as neutrophils, to the sites of infection (Di Paolo et al. 
2014). 
Like macrophages, dendritic cells (DCs) produce proinflammatory cytokines, including 
IL-12, IL-1 and TNF-α in response to Ad infection (Philpott et al. 2004; Zhang et al. 2001). 
However, compared to macrophages, DCs are much more efficient antigen presenting cells 
(APCs) and are therefore extremely important in directing the adaptive immune response to Ad 
infection. Recognition of Ad by PRRs stimulate DCs to produce proinflammatory cytokines and 
results in DC maturation and upregulation of costimulatory molecules (Hensley and Amalfitano 
2007; Lore et al. 2007; Molinier-Frenkel et al. 2002). The cytokines produced by innate immune 
cells, in conjunction with antigen presentation via MHCII molecules direct the adaptive immune 
response to Ad (discussed in a later section). 
 During Ad infection type I IFNs, produced from infected cells, directly activate NK cells 
(Zhu, Huang, and Yang 2008). These activated NK cells are then able to perform effector 
functions including killing of virally infected cells and production of IFN-γ and TNF-α. These 
cytokines are important for recruitment and activation of immune cells. Furthermore, IFN-γ 
plays an important role in regulating the adaptive immune response to Ad infections. Neutrophils 
are also recruited to sites of Ad infection where they internalize opsonized virus and kill virally 
infected cells (Cotter, Zaiss, and Muruve 2005). As a result, they are responsible for the majority 
of early tissue injury during Ad infection.  
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 Ad infection triggers TLRs, NLRs, and RLRs that contribute to the innate immune 
response to Ad. As mentioned above, interactions during Ad attachment result in production of 
IL-1α leading to IL-1R1 signaling. Additionally, pathogen associated molecular patterns 
(PAMPs) generated during adenovirus entry and replication are recognized by innate sensors. 
 Several TLRs are thought to recognize and respond to Ad infection. Both TLR2 and 
TLR4 on the cell surface have been shown to contribute to the innate immune response to Ad 
(Appledorn et al. 2008; Doronin et al. 2012). Following partial disassembly of the viral capsid in 
the late endosome, TLR9 senses viral dsDNA leading to MyD88 dependent activation of NF-κB. 
Activated NF-κB then  induces upregulation of proinflammatory cytokines including IL-6 and 
IL-12 (Cerullo et al. 2007).  TLR9 is the main point of Ad DNA recognition in plasmacytoid 
DCs and is important for generating a type I IFN antiviral response (Basner-Tschakarjan et al. 
2006). Type I IFN responses in primary macrophages and conventional DCs are induced by 
detection of Ad DNA by TLR independent cytosolic sensors as well as by TLR9 (Nociari et al. 
2007; Zhu, Huang, and Yang 2007).  
 Following endosomal escape, viral DNA in the cytosol can be detected by sensors such 
as DNA-dependent activator of IFN-regulatory factors (DAI), generating IRF3 and IRF7 
mediated type I IFN responses (Fejer et al. 2008; Takaoka et al. 2007). Additionally, Ad can 
activate the Nod-like receptor NLRP3 (Barlan et al. 2011; Muruve et al. 2008). NLRP3, along 
with the adaptor protein ASC, recruits caspase-1 into a complex known as the NLRP3 
inflammasome. Upon activation of this inflammasome complex caspase-1 processes pro-IL-1 
and pro-IL-18 into their mature forms which can then be secreted. Virally associated RNAs (VA-
RNAs), expressed early during Ad infection, can also be detected by innate sensors. RIG-I 
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recognizes these dsRNAs which activates production of type I IFNs (Yamaguchi et al. 2010). 
(Figure 3A) 
 Cytokines produced in response to innate sensing of Ad infection activate professional 
APCs and recruit immune cells to the site of infection. Therefore, not only are they important 
mediators of the innate immune response to Ad infection but they also help direct the adaptive 
immune response. IL-6 supports B cell proliferation and, along with type I interferons, promotes 
optimal B and T cell responses to antigen (Hirano et al. 1986; Tough, Borrow, and Sprent 1996; 
Vasconcellos et al. 1999). Additionally, IL-6 and IL-1 support TH17 differentiation (Veldhoen 
et al. 2006), whereas IL-12 and IL-18 produced in response to Ad infection help to support 
differentiation of naïve T cells into the TH1 subtype (Dinarello 1999; Hsieh et al. 1993). (Figure 
3B) 
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Figure 3. Immune Activation in Response to Adenovirus Infection. (A) Following partial 
disassembly of the viral capsid within the endosome, TLR9 senses viral dsDNA. TLR9 activates 
NFκB, leading to the expression of proinflammatory cytokines. Viral DNA in the cytosol is 
sensed by DNA-dependent activator of IFN-regulatory factors (DAI), which activates IRF3 and 
IRF7 to induce a type I interferon response. Additionally, virally associated RNAs (VA-RNAs) 
are detected by RIG-I which activates production of type I interferons. Ad DNA has also been 
shown to activate the NLRP3 inflammasome. Inflammasome activation leads to the proteolytic 
cleavage of pro-IL-1 and pro-IL-18 into their mature forms. (B) In conjunction with antigen 
presentation via MHCII, cytokines produced in response to innate sensing of Ad infection direct 
the adaptive immune response to Ad. IL-12 and IL-18 produced in response to Ad support the 
differentiation of naïve CD4+ T cells into the TH1 subset. TH1 cells secrete cytokines that support 
cell mediated immunity and clearance of intracellular pathogens. Differentiation of CD4+ T cells 
into the TH17 subset is supported by cytokines including IL-6 and IL-1 which are produced in 
response to Ad infection. TH17 cells are important for clearance of extracellular pathogens. IL-4 
supports differentiation of TH2 cells, which support humoral immunity. 
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Adaptive Immune Response to Adenovirus 
 During Adenovirus infection CD8+ T cells play a primary role in the recognition and 
destruction of virally infected cells (Yang, Ertl, and Wilson 1994). Virally infected cells present 
viral antigen on MHCI molecules which can then be recognized by antigen specific cytotoxic T 
cells (CTLs). In order to become activated CTLs must encounter antigen in the context of MHCI 
along with a second costimulatory signal. The interaction between CD28 on CD8+ T cells and 
CD80/86 on the target cell can serve as the second costimulatory signal (Linsley et al. 1991). 
Alternatively, the costimulatory signal can come from CD4+ T cells including the TH1 subset 
(Yang et al. 1995). 
 Upon activation CTLs use a variety of mechanisms to kill virally infected cells. One 
mechanism by which CTLs kill target cells is by releasing cytotoxic granules containing perforin 
and granzymes. Perforin forms a pore in the target cell membrane, thereby allowing granzymes 
to enter the infected cell. Once inside the cell, granzymes cleave and activate caspase proteins 
leading to apoptosis of the target cell.  Additionally, binding of FasL on the surface of CTLs to 
its receptor, Fas, on the surface of target cells induces a caspase signaling cascade that leads to 
apoptosis. CTLs further support immune defenses against pathogens by releasing 
proinflammatory cytokines such as TNF-α and IFN-γ. IFN-γ production enhances leukocyte 
migration to sites of infection, increases expression of MHC molecules, and promotes isotype 
switching (Carneiro et al. 2015; Rubtsova et al. 2016; Thelemann et al. 2014).  
 In addition to CD8+ T cells Adenovirus infection also induces a CD4+ T cell response. 
APCs present viral antigen in the context of MHCII to naïve CD4+ T cells and engage antigen 
specific TCRs on the T cell surface. TCR engagement along with engagement of costimulatory 
molecules induces activation of antigen specific T cells. During this activation cytokines play a 
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critical role in the differentiation of naïve CD4+ T cells into distinct T helper (TH) effector 
populations (Zhu, Yamane, and Paul 2010). IL-12 and IL-18 support the differentiation of naïve 
CD4+ T cells into TH1 cells, whereas IL-4 supports the differentiation of TH2 cells (Gutcher and 
Becher 2007). Differentiation into TH17 cells is supported by cytokines such as IL-1, IL-6, and 
TGF (Nalbant and Eskier 2016). (Figure 3B) 
 The different T helper subsets mediate distinct effector functions during Ad infection. 
TH1 cells secrete cytokines, including IL-2 and IFN-γ, that support cell mediated immunity and 
clearance of intracellular pathogens. Specifically, IFN-γ helps to induce CTL differentiation and 
macrophage activation. As described previously, CTLs and macrophages are important 
responders to Ad infection. TH2 cells support humoral immunity and are characterized by 
secretion of IL-4. Cytokines, such as IL-4, secreted by TH2 cells support the differentiation of B 
cells into plasma cells which produce neutralizing antibodies against Ad (Chen and Ross 2007).  
The TH17 response to Ad infection is not well characterized.  Given that innate immune 
responses to Ad infection result in secretion of cytokines important for TH17 differentiation, such 
as IL-6 and IL-1, it is likely a TH17 response is induced during Ad infection. Indeed, recent 
studies have shown that a TH17 response is induced during mouse adenovirus type 1 infection 
(McCarthy et al. 2014). The role of TH17 cells in adenovirus infection remains unclear, as this 
subset is generally involved in clearance of extracellular bacteria, however it has been shown 
that IL-21 and IL-17 produced by TH17 cells support germinal center formation and IgG class 
switching (Mitsdoerffer et al. 2010).  
 In addition to generating effector T cells, Ad infection also induces formation of memory 
T cells that can rapidly respond to future infections. Both CD4+ and CD8+ memory T cells are 
induced during Ad infection (Barnes et al. 2012; Bolinger et al. 2013). There are two main types 
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of memory T cells. Central memory T cells reside primarily in lymph tissues and rapidly 
proliferate following restimulation with antigen. In contrast, effector memory T cells are found 
in the peripheral circulation and tissues. Effector memory T cells rapidly and efficiently respond 
to antigen; however, they have limited proliferative capabilities compared to central memory T 
cells. 
 Naïve B cells in the lymph nodes encounter soluble antigen as well as antigen on 
follicular DCs (FDCs) or other APCs (Koppel et al. 2005; Qi et al. 2006). During Ad infection 
binding of viral antigen to the BCR on the surface of naïve B cells provides the primary signal 
for B cell activation. Interactions with coreceptors including CD19 and integrins strengthens this 
activation (Harwood and Batista 2010). The receptor bound antigen is then internalized, 
digested, and complexed with MHCII molecules on the B cell surface. A second activation signal 
is provided by interactions with antigen specific CD4+ T cells and MHCII complexed antigen on 
the surface of the B cell. In addition, CD40 on the B cell surface engages with CD40 ligand on 
the surface of the T cell in order to fully activate the B cell to proliferate and develop into either 
memory B cells or antibody secreting plasma cells (Good-Jacobson and Tarlinton 2012).  
Ad-specific antibodies bind to Ad in the bloodstream, preventing cell entry and promoting 
opsonization of the virus by macrophages (Yu et al. 2013). 
Adenovirus Vaccine Vectors 
Adenoviruses have been explored extensively as tools for gene replacement therapy, 
however the strong innate and adaptive immune responses against these vectors have limited 
their utility. While the potent immune response to Ad vectors poses a challenge for gene therapy, 
it makes Ad an ideal vaccine vector candidate. In addition to inducing antibody responses against 
vaccine antigens, Ad vectors are potent T cell adjuvants. They have been shown to induce both 
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CD8+ and CD4+ T cell responses to vaccine antigens (Appaiahgari and Vrati 2015) (Figure 4). 
Furthermore, Ads have a broad cellular tropism, can be grown to high titers in tissue culture, 
induce high levels of transgene expression, and have a well characterized and easy to manipulate 
genome.  
 Detailed understanding of Ad molecular biology allowed for the development of first-
generation replication-incompetent (FGV) vectors. These vectors lack the E1 gene, a critical 
transcriptional activator for viral replication, and thus are unable to replicate outside of E1-
complementing cell lines. Many vectors also contain deletions in the E3 gene, allowing for 
increased transgene insertion capacity up to 7.5kb.  Typically, robust transgene expression is 
achieved by having transgene expression under the control of a constitutively active promoter 
such as the cytomegalovirus (CMV) IE promoter. The Ad vectors used in these studies are E1/E3 
deleted replication-incompetent vectors containing the CMV IE promoter.  
One of the earliest studies using Ad vectors, performed by Xiang et al, used E1 deleted 
Ad5 vectors to induce protection against the rabies virus. This Ad5 vector expressing the rabies 
virus glycoprotein induced protective titers of neutralizing antibodies, as well as CD8+ and CD4+ 
T cell responses against the vaccine antigen (Xiang et al. 1996).  Since then Ad5 vectors have 
been successfully used to generate immune responses against a number of pathogens, including 
malaria, influenza, and HIV (Chuang et al. 2013; Kanagavelu et al. 2014; Peters et al. 2013).  In 
general, Ad based vectors have been shown to induce superior antigen specific antibody titers 
and CD8+ T cell responses compared to other subunit vaccines (poxvirus, vaccinia virus, DNA 
vaccines, etc.) (Tatsis and Ertl 2004). 
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Figure 4. Induction of Transgene-Specific Immune Responses Following Immunization 
with Adenovirus Vectors. Intramuscular immunization with replication defective Ad vectors 
results in infection (non-productive) of cells followed by transgene expression. Innate sensing of 
viral components results in expression of proinflammatory cytokines and type I interferons. 
Expressed proteins undergo proteasomal degradation and are presented to CD8+ T cells via 
MHCI. Alternatively, proteins may be secreted and taken up by antigen presenting cells (APCs). 
Activated APCs then migrate to the draining lymph node where they are able activate CD8+ and 
CD4+ T cells and B cells. Taken from (Ewer et al. 2016).  
 
One major limitation of Ad vectors is preexisting immunity. As a result of natural Ad 
infection, the majority of individuals have neutralizing antibodies against Ad. Depending on the  
region, preexisting immunity to Ad5 ranges from 30-100% (Appaiahgari and Vrati 2015). 
Neutralizing antibodies against the Ad vector have been shown to reduce Ad uptake and 
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transgene expression, leading to a greatly diminished transgene specific immune response (Tatsis 
and Ertl 2004). Several approaches have been investigated in order to try and circumvent the 
issue of preexisting immunity to Ad5 vectors, including the use of alternative serotype Ad 
vectors and capsid displayed antigen. 
 In recent years replication defective chimpanzee Ad vectors (ChAd) and human Ad 
vectors with lower seroprevalence have been explored as a means to overcome the issue of 
preexisting immunity. Human Ad4 and Ad6 vaccine vectors have been used in vaccine 
development for influenza and HCV, respectively. ChAd3 vectors have also been used in HCV 
vaccine development. In human trials Ad6 and ChAd3 based vaccines generated CD8+ and CD4+ 
T cell responses, including both central and effector memory populations (Appaiahgari and Vrati 
2015). Strong CD8+ and CD4+ T cell responses have also been demonstrated in human subjects 
following immunization with human Ad35 vectors expressing Mycobacterium tuberculosis 
antigens (Abel et al. 2010). These studies indicate that alternative Ad vectors are able to induce 
anti-transgene immune responses while also overcoming the obstacle of preexisting immunity. 
 Another approach that has been used to circumvent preexisting immunity is to use capsid 
displayed epitopes of the vaccine antigen. Foreign sequences can be inserted into the capsid 
proteins hexon, penton, fiber and protein IX. Replacement of the hexon hypervariable regions 
(HVRs) with epitopes from the vaccine antigen allows for presentation of the antigen and 
prevents recognition of the Ad vector by neutralizing antibodies raised against the HVRs 
(Bradley et al. 2012).   
This document describes the development of novel Ad5-vectors that are capable of 
inducing potent T and B cell immunity to transgene antigens. Furthermore, this work shows that 
these vectors are able to provide protection against cutaneous MRSA infection. The results 
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described in this work contribute to our understanding of the adjuvant properties of Ad5 vectors 
and the correlates of vaccine mediated protection against MRSA infections. Importantly, this 
work shows that Ad5-based vectors represent a novel potential S. aureus vaccine strategy.  
 
 
 
 
 31 
CHAPTER TWO 
MATERIALS AND METHODS 
Cells Lines and Cell Culture 
Our lab obtained 2935 cells as a gift from Glen Nemerow (Smith et al. 2010). 
RAW264.7 cells and HeLa cells were purchased from ATCC. All tissue culture reagents were 
obtained from Mediatech and HyClone. 2935 and HeLa cells were maintained in Dulbecco 
Modified Eagle Medium (DMEM) and supplemented with 1mg/mL streptomycin, 100IU/mL 
penicillin, 0.25mg/mL amphotericin B, non-essential amino acids, 10% fetal bovine serum 
(FBS), 1mM sodium pyruvate, 2mM glutamine, and 10mM HEPES buffer.  RAW264.1 cells and 
murine splenocytes were cultured in RPMI1640 media containing the same supplements as 
DMEM.  
Generation of Recombinant Virus 
 Ad5gfp was generated as previously described (Wodrich et al. 2010). To generate 
Ad5ClfA and Ad5SdrD we used the Ad5Easy system as described previously (He et al. 1998; 
Luo et al. 2007). To summarize, we cloned DNA containing the sequence for the ligand binding 
domain of ClfA (amino acids 40-559) or SdrD (amino acids 53-853) from S. aureus strain 
USA300 into a shuttle vector (Foster et al. 2014; McDevitt et al. 1995; Wang et al. 2013). We 
then used recombineering to insert the shuttle vector into an E1/E3 deleted Ad5 genome. We 
confirmed expression of ClfA or SdrD by western blot of Ad5ClfA or Ad5SdrD infected cell 
lysates. 
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Ad5PFgfp was generated using the galK recombineering system described by Warming 
et al. (2005). Primers encoding the galK sequence flanked by sequences homologous to the 
intended insert site within the pIX gene were used to amplify galK from a plasmid (pgalK). 
pgalK was obtained from the NCI BRB Preclinical Repository (NCI-FCRDC). Homologous 
recombination was then used to insert the galK cassette into the end of the pIX gene, then 
positive selection by growth on minimal media plates containing galK was used to obtain clones 
of successful recombinants. To replace galK with the flag-fliC35 sequence, we amplified flag-
FliC35 products using primers for flag-FliC35 flanked by sequences homologous to either end of 
the galK cassette. We then used homologous recombination to replace the galK cassette with 
flag-fliC35. To identify successful recombinants, we grew bacteria on minimal media plates 
containing X-gal, which is converted to a toxic metabolite in cells still containing the galK 
cassette. We were therefore able to use negative selection to screen for successful recombinants. 
Finally, we used PCR amplification of the pIX gene to confirm successful recombination.  
Virus Purification 
 Viruses were propagated using HEK293 cells. We purified the viruses by subjecting them 
to two rounds of cesium chloride gradient centrifugation followed by dialysis in 40mM Tris, 
150mM NaCl, 1mM MgCl2 and 10% glycerol (Wiethoff et al. 2005). To determine virus 
concentration, we performed Bradford assays, with 1mg of protein corresponding to 4x109 viral 
particles (Bio-Rad Laboratories, Inc.). Viruses were aliquoted, frozen in liquid nitrogen, then 
stored at -80. We determined viral titers of Ad5gfp and Ad5PFgfp by serially diluting virus on 
HeLa cells and using flow cytometry to quantitate the number of GFP expressing cells. To 
determine the titers of Ad5ClfA and Ad5SdrD we serially diluted virus on HeLa cells then used 
IFA to detect Ad hexon.  
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Bacterial Strains and Cultures 
 USA300 and SA113 strains of S. aureus were a gift from Dr. Katherine Radek. RN4220 
was a gift from Dr. Francis Alonzo III. To construct USA300gfp and RN4220gfp a PCR 
amplicon of GFP was generated, digested, and subcloned into pJC1111. pJC1111 was then stably 
integrated into the S. aureus SaPl-1 site using phage transduction as previously described 
(Alonzo et al. 2012; DuMont et al. 2014). pJC1111 was a gift from Dr. Francis Alonzo III. S. 
aureus was gown at 37 on tryptic soy broth (TSB) solidified with agar or in liquid TSB culture 
shaking at 180 rpm.  
USA300 Whole Cell Lysate Preparation 
 USA300 whole cell lysate was prepared by incubating bacterial culture with lysostaphin 
(1:100) and homogenizing using a Dounce homogenizer. Following homogenization lysates 
were treated with DNase (1:100) and centrifuged at 4. The concentration of protein in the 
supernatant of the lysate was then determined by Bradford assay. 
Recombinant Protein Construction and Purification 
 We used PCR to amplify DNA encoding for amino acids 40-559 of ClfA, 53-853 of 
SdrD, 53-606 of SdrE, and 37-603 of FnBPA from USA300. These amino acids encode for 
ligand binding regions of ClfA, SdrD, SdrE and FnBPA (Deivanayagam et al. 2002; Foster et al. 
2014; Keane et al. 2007; McDevitt et al. 1995; Wang et al. 2013; Wann, Gurusiddappa, and 
Hook 2000). We then ligated these PCR products into the pGEMT-easy vector. The resulting 
pGEMT-easyClfA, pGEMT-easySdrD, pGEMT-easySdrE, and pGEMT-easyFnBPA vectors 
were digested with NdeI and BamHI to release the ClfA, SdrD, SdrE and FnBPA inserts, and 
those fragments were then ligated into the protein expression vector pET15b. The pET15b vector 
allows for IPTG inducible, T7 promoter driven expression of recombinant proteins and encodes 
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for a N-terminal 6X His-tag. We confirmed successful ligation reactions by digesting 
pET15bClfA, pET15bSdrD, pET15bSdrE and pET15bFnBPA with NdeI and BamHI. We ran the 
digestion reactions on agarose gels using gel electrophoresis to confirm the identity of bands 
corresponding to ClfA, SdrD, SdrE or FnBPA sequences.  
 To express the recombinant proteins, we transformed BL21 E. coli with pET15b vectors 
encoding for ClfA, SdrD, SdrE or FnBPA. To obtain recombinant GFP we transformed BL21 
cells with pETHis6GFPTEVLIC (Addgene cat #29663). We grew cultures overnight at 37 in 
LB with ampicillin or kanamycin (pETHis6GFPTEVLIC) to maintain expression of the pET 
vectors. The next day we diluted the overnight cultures 1:20 in 500mLs of LB with ampicillin or 
kanamycin and continued growing the cultures at 37 until they reached an OD600 of 0.6. At that 
time, we induced protein expression by addition of 1mM IPTG and continued growing cultures 
for an additional 4 hours. We harvested cells by centrifugation at 0. All subsequent steps were 
performed on ice or at 0, and 1:100 PMSF was added to all buffers to minimize protein 
degradation. We lysed cells by incubating the cell pellet in 20mLs of 1% Triton X-100, 
0.5mg/mL lysozyme and 1:100 DNAse in 50mM PBS. The solubilized pellets were then 
centrifuged at 13,000xG for 15min and supernatant, containing the soluble recombinant proteins, 
was collected. 
 We added lysozyme and glycerol to the supernatant for a final concentration of 10mM 
lysozyme and 10% glycerol. We then loaded the supernatant onto 0.5mL TALON cobalt resin 
columns (Clontech cat #635501). Column flow through was reloaded onto the column one time, 
followed by 10mL of Wash Buffer 1 (50mM Phosphate, 500mM NaCl, 10mM Imidazole and 1% 
triton X-100) and 10 1mL washes with Wash Buffer 2 (50mM Phosphate, 500mM NaCl, 10mM 
Imidazole). We eluted protein using 150mM Imidazole in 50mM PBS and dialyzed protein in 
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PBS with 1% glycerol for 4hrs. Protein concentration was determined by Bradford assay. Sample 
purity was confirmed by 15% SDS-PAGE followed by Coomassie stain.  
Western Blot Analysis 
 To demonstrate that immunization with recombinant proteins elicit antibodies that 
recognize purified proteins as well as USA300 whole cell lysate (WCL) we utilized western blot 
analysis. We loaded 2μg of purified recombinant ClfA, SdrD, SdrE or FnBPA and 2μg of 
USA300 WCL onto 15% polyacrylamide gels and performed SDS-PAGE. Proteins were 
subsequently transferred to nitrocellulose and immunoblotted for ClfA, SdrD, SdrE or FnBPA 
using 1:250 diluted serum from mice immunized with the respective recombinant protein. 
Primary antibody was detected using HRP-conjugated anti-ms IgG at a 1:1000 dilution.  
 We performed western blotting to confirm the expression of ClfA and SdrD in cells 
following infection with Ad5ClfA or Ad5SdrD, respectively. 2935 cells were plated at 300,000 
cells per well in a 6-well plate. The following morning cells were infected with 300ppc of either 
Ad5ClfA or Ad5SdrD. 48hrs post infection cells were harvested and cell lysates were subjected 
to SDS-PAGE (alongside 2ng recombinant ClfA or SdrD run as positive controls) followed by 
transfer to a nitrocellulose membrane and immunoblotted for ClfA or SdrD using 1:500 diluted 
serum from ClfA or SdrD immunized mice. Both membranes were also blotted for Actin (Sigma 
cat #A5441) which served as a loading control. HRP-conjugated anti-ms IgG (1:1000) was used 
to detect the primary antibody. 
Mouse Experiments 
 Mice used in these studies were either C57BL/6 wildtype mice (Jackson laboratories cat 
#000663) or BALB/c mice (Jackson laboratories cat #000651) aged 6-12 weeks. All studies were 
approved by the Institutional Animal Care and Use Committee of Loyola University Chicago 
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(Maywood, IL). All immunizations were performed by intramuscular vaccination of 50μl into 
the left quadricep. For protein immunizations purified recombinant ClfA, SdrD, SdrE and/or 
FnBPA were adsorbed to aluminum hydroxide (alum) using 25μl of alhydrogel for a 1:1 protein 
to alum solution ratio. Alum was purchased as Alhydrogel gel suspension from Invivogen (cat # 
21645-51-2). To obtain polyclonal serum raised against either purified recombinant ClfA, SdrD, 
SdrE or FnBPA, 6-8 week old C57BL/6 mice were immunized with 10μg of protein followed by 
a second immunization 21 days later. Mice were sacrificed and serum collected 21 days after the 
last immunization. 
 To compare the immune response between ClfA and Ad5ClfA immunized animals, 
C57BL/6 mice were immunized with either 109 viral particles (vp) of Ad5ClfA or 2μg of 
recombinant ClfA (administered as a protein-Alum solution). For immunization and challenge 
experiments evaluating the ability of Ad5ClfA and Ad5SdrD to provide protection against 
USA300 challenge, C57BL/6 mice aged 6-8 weeks were immunized with 109 vp of Ad5ClfA 
and 109 vp of Ad5SdrD. To compare the protective effects of Ad immunization to those of 
protein immunization, additional animals were immunized with 2μg of each ClfA, SdrD, SdrE, 
and FnBPA. Ad5gfp (109vp) immunization was used as a vector control, and PBS (50μl) 
immunization was used as an unimmunized control. All other immunizations, including those 
comparing Ad5gfp and Ad5PFgfp vectors, were performed on BALB/c mice using 1010 vp of the 
respective virus. For all single immunization experiments, animals were sacrificed and serum, 
splenocytes and lymph nodes were collected 10 days post immunization.  
 For all S. aureus immunization and challenge experiments mice were immunized as 
described above. Mice were then challenged with either USA300, USA300gfp, or RN4220gfp 28 
days post immunization. Mice were challenged by intradermal injection at four sites on their 
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back. At each of the four injection sites, 2x106 CFU of bacteria resuspended in PBS were 
administered in a 1:1 ratio with Cytodex microcarrier beads in PBS (Sigma cat #C646-5G 1.60-
87μm). Total volume per injection site was 100μl. Three to six days following challenge mice 
were sacrificed and serum, splenocytes, lymph nodes and wounds were collected. For vaccine 
efficacy experiments immunized mice were challenged with varying doses of USA300 as 
described above. To confirm that recombinant proteins could generate an IL-17 response, 
unimmunized mice were infected as described above with USA300, SA113, or mock infected 
using PBS. Six days post infection mice were sacrificed and splenocytes were collected.  
Determination of Wound Bacterial Load and Wound Size 
 To determine the wound bacterial load following intradermal challenge, we isolated 
wound biopsy punches and digested them with 10U/mL Collagenase (Sigma cat #C0130) for 1 
hour at 37. The samples were then homogenized in 1mL of sterile PBS by 1.00mm Zirconium 
silica beads. We then made serial ten-fold dilutions of the homogenized samples in sterile PBS 
and plated dilutions onto TSA plates. Plates were incubated at 37 overnight. The following day 
we determined the number of colony forming units (CFUs) present and multiplied by the 
appropriate dilution factor to determine CFUs/mL. Lesion area was determined by measuring the 
diameter of the wound and using the equation A= πr2. 
IL-17 ELISPOT 
 ELISPOT assays were performed using the Mouse/Rat IL-17A ELISPOT Ready-SET-
Go! kit from eBioscience (cat # 88-7370). Briefly, ELISPOT plates (Millipore cat #MAIPS4510) 
were coated with an anti-IL-17A capture antibody overnight at 4. Plates were blocked with 
complete RPMI for 1 hour at room temperature then splenocytes were added to the wells at 
1x106 cells/well. Splenocytes were harvested by homogenizing spleens on a mesh filter in RPMI. 
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Cells were spun down at 300xg for 5 minutes then resuspended in 2mL of red blood cell lysis 
buffer for 2 minutes and resuspended in 3mLs of RPMI. Finally, cells were again spun down and 
the pellet was resuspended in 2mL of RPMI and plated. Antigen (ClfA, SdrE, or USA300 WCL) 
was added to the appropriate wells for a final concentration of 2μg/mL. Plates were incubated for 
42 hours at 37 then washed with PBST (0.05% tween) and incubated with a biotinylated anti-
IL-17A detection antibody at room temp for 2 hours. Following the 2 hour incubation the plates 
were washed again then incubated with Avidin-HRP at room temperature for 45 minutes. After 
washing the plates, we developed them by adding AEC substrate (Sigma #AEC101) and 
incubating them until spots developed.  
Ex Vivo Splenocyte Stimulation 
We harvested splenocytes as described above for ELISPOT. We then plated cells in a 96-
well plate at a density of 1x106 cells/well and stimulated them with specific antigens. 
Splenocytes were stimulated with Ad5 (10,000 particles per cell) or ClfA, SdrD, or GFP 
(1μg/mL). Cells were left untreated to serve as an unstimulated control or incubated with 
20ng/mL PMA and 1μg/mL Ionomycin to serve as a positive control. Cell free supernatants were 
harvested 24hrs (for IFNγ ELISAs) or 5 days (for IL-17 ELISAs) after stimulation and subjected 
to ELISA to detect IFNγ or IL-17 as described below. 
ELISA 
Mouse serum was subjected to ELISAs to determine endpoint dilution titers and IgG 
isotype responses to antigen. Blood was obtained from sacrificed mice by the cardiac puncture 
method. Blood was kept on ice for 1 hour then spun down at 8000 rpm for 5 minutes to separate 
out coagulated RBCs. Serum was aliquoted and stored at -80 until use.  
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High binding ELISA plates (Costar ca #07-200-35) were coated overnight at 4 with 
1μg/mL of antigen in coating buffer (BioLegend cat #421701) while shaking. The next day 
plates were washed 4 times in PBST (0.05% tween) and blocked with assay diluent (ebioscience 
cat #00-4202-56) for 1 hour. We washed plates again then added 100μ/well of serially diluted 
mouse serum and incubated the plates shaking at room temperature for 2 hours. After washing 
the plates, we added 100μl/well of 1:1000 diluted HRP conjugated anti-mouse IgG (Fc) (Abcam 
ab97265) and incubated plates for another hour. We washed the plates then developed them 
using 50μl/well TMB Substrate and stopped the reaction using 1M sulfuric acid. Plates were read 
on a KC Junior plate reader at 450nm. Dilutions curves were used to determine the antibody 
endpoint dilution titer (ELISA units), defined as the dilution at which the absorbance value is 3 
standard deviations above that of PBS-immunized control mice. ELISAs to determine IgG 
isotypes were performed as described above except that a single serum dilution was used and the 
secondary antibodies used were specific to IgG1, IgG2b, IgG2c, or IgG3. 
BioLegend Mouse IFNγ (Cat No. 430801) and BioLegend Mouse IL-17A (Cat No. 
432501) kits and protocols were used to measure IFNγ and IL-17 levels in cell free supernatants 
following ex vivo splenocyte stimulation. To summarize, plates were coated overnight at 4 
with the appropriate capture antibody, then washed, blocked and incubated with diluted 
standards and samples at room temperature for 2 hours while shaking. After washing, plates were 
incubated with the appropriate biotinylated detection antibody for 1hr, washed and incubated 
with Avidin-HRP. Plates were developed with TMB substrate and read as described above. The 
IFNγ or IL-17 response was determined by comparing test OD450 values to a standard curve.  
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Opsonophagocytic Assays (OPAs) 
 OPAs were used to evaluate the ability of serum from immunized animals to mediate 
opsonophagocytosis of S. aureus. USA300 cultures were grown overnight in TSB at 37 while 
shaking. The following day we diluted the cultures 1:100 and incubated them at 37 for an 
additional 3 hours. After 3 hours the cultures were spun down at 4000 rpm for 6 minutes, washed 
with sterile PBS and resuspended in 5mL of sterile PBS. Cultures were normalized to an OD600 
corresponding to 1x108 CFU/mL. One mL of normalized culture was spin down, resuspended in 
1mL of RPMI, 10mM HEPES, and 1% serum mouse serum (collected as previously described) 
and incubated, shaking, at room temperature for 30 minutes. After 30 minutes cultures were spun 
down, washed and resuspended in 1mL RPMI with 10mM HEPES.  
10μl of culture was added to RAW264.7 cells (in RPMI, 10mM HEPES) plated in 96 
well plates at a cell density of 1x105.  Bacteria and RAW264.7 cells were synchronized by 
spinning plates at 1500 rpm for 7 minutes. Plates were either incubated at 37 (5% CO2) for 30 
minutes (T30) or immediately placed on ice (T0). Following incubation, T30 samples were 
treated with 50μg/mL gentamicin for 15 min, then a 1% saponin solution was used to 
permeabilize RAW264.7 cell membranes. T0 samples were treated with 1% saponin 
immediately following synchronization. Serial 10-fold dilutions of T0 and T30 samples were 
plated onto TSA plates and the CFU/mL for each sample was determined as described 
previously. Percent bacterial uptake was calculating by normalizing the CFU/mL of the T30 
sample to the CFU/mL of the T0 sample.  
RT-qPCR 
 RNA was isolated from mouse tissues using TRIzol Reagent (Life Technologies cat 
#15596-026) and its accompanying protocol. 2μg of RNA was DNase I treated (Fermentas cat 
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#EN0521) and reverse transcribed to single strand cDNA using Fermentas RevertAid First 
Strand cDNA Synthesis Kit (cat #K1621). The cDNA was then used to perform qPCR on the 
BioRad CFX96. We used BioRad IQ SYBR Green Supermix (cat #170-8880) and the primer 
sets shown in Table 1. Relative expression was determined using the 2-∆∆CT method (Livak and 
Schmittgen 2001) where the expression of the genes of interest were normalized to GAPDH 
expression within each sample type and the gene of interest expression level in control samples 
is set to 1. 
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Table 1. Primer Sequences for qPCR 
Primer name Sequence  
msIFNγ forward cggcacagtcattgaaagccta (Xia et al. 2010) 
msIFNγ reverse gttgctgatggcctgattgtc  
msIL-17 forward aaggcagcagcgatcatcc (Krauthausen et al. 2011) 
msIL-17 reverse ggaacggttgaggtagtctgag  
msIL-21 forward gccagatcgcctcctgatta (Pesce et al. 2006) 
msIL-21 reverse cggggtaccggagagatgctgatg  
msCXCL1 forward atccagagcttgaaggtgttg (Roy et al. 2012) 
msCXCL1 reverse gtctgtcttctttctccgttactt  
msCXCL2 forward gaacaaaggcaaggctaactga (Narita et al. 2010) 
msCXCL2 reverse aacataacaacatctgggcaat  
msCXCL5 forward acagtgccctacggtggaagt (Roy et al. 2012) 
msCXCL5 reverse  cgaggtgcattccgcttagctt  
msGAPDH forward tgcccccatgtttgtgatg (Martowicz, Grass, and Bresnick 2006) 
msGAPDH reverse tgtggtcatgagcccttcc  
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Immunofluorescence Microscopy 
 A 3mL culture of USA300 was grown in TSB overnight at 37. The following day 
0.5mL of overnight culture was spun down at 4000 rpm for 6 minutes and used to inoculate 
20mL of TSB. The culture was allowed to grown at 37 for 2 hours, then 0.5mL was spun 
down, washed 3 times with sterile PBS, applied to glass coverslips and allowed to air dry for 30 
minutes. Cells were fixed in 95% ethanol, washed with PBS then incubated with mouse serum 
(1:100) overnight at 4. The following day the coverslips were washed in PBS then incubated 
with an anti-mouse-568 secondary antibody (1:4000) and counterstained with DAPI for 2 hours 
at room temperature.  The coverslips were then mounted on glass slides with Flouro-Gel 
(Electron Microscopy Sciences) and images were acquired using a confocal microscope. 
Reagents and Antibodies 
 Assay Diluent (cat #00-4202-56) and TMB substrate (cat #00-4201-56) used for ELISA 
were purchased from eBioscience. Phorbol-12-myristate-13-acetate (PMA), Ionomycin, and 
Lysostaphin were purchased from Sigma-Aldrich.  HRP-conjugated anti-mouse IgG isotype 
antibodies were purchased from Southern Biotech (cat #5300-05B). HRP-conjugated anti-mouse 
IgG secondary antibody was purchased from Abcam (cat #ab97265). The Goat anti-mouse IgG 
secondary antibody, conjugated to Alexa Fluor 568 used for immunofluorescence microscopy 
was purchased from ThermoFisher (cat #A-11004).  SuperSignal West Dura Extended Duration 
Substrate was used to develop and image western blots (Fisher cat #34075). All other reagents 
were purchased from Fisher Scientific. 
Statistics 
We assessed statistical significance (p < 0.05) between two groups using the Student’s T Test. 
Data are presented as the mean ± SEM. 
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CHAPTER THREE 
RESULTS 
Immunization with Recombinant S. aureus Proteins Induces High Titer Antibodies 
 It has previously been shown that protection from S. aureus induced disease in mice 
correlates with production of antibodies against several S. aureus surface adhesion proteins, 
including FnBPs, ClfA, and Sdr proteins (Kim et al. 2011). However, emerging evidence 
suggests that protection against S. aureus infection likely requires T cell help, including TH17 
and TH1 responses (Lin et al. 2009). Given that Adenovirus vaccine vectors are potent inducers 
of T cell responses, we sought to use replication defective Adenovirus vectors to express 
domains from S. aureus surface proteins. I hypothesized that Adenovirus vaccine vectors would 
induce more potent T cell responses to vaccine antigens than protein in Alum immunization and 
would therefore provide greater protection against MRSA challenge. To be able to compare the 
protective effects of Adenovirus vaccines with recombinant protein in Alum immunization we 
generated recombinant ClfA, SdrD, SdrE, and FnBPA proteins corresponding to the ligand 
binding domains of each. We also generated E1, E3-deleted Ad5 vectors expressing these same 
proteins under the control of the CMV promoter. 
 To confirm that the recombinant proteins were able to induce an antibody response we 
immunized C57BL/6 mice with the individual recombinant proteins. Following prime and boost 
immunizations with 10μg of the appropriate recombinant protein, serum was harvested and used 
to perform western blot analysis. Purified recombinant protein (either ClfA, SdrD, SdrE, or 
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FnPBA) was run alongside USA300 WCL on a 15% polyacrylamide gel. The gels were then 
transferred to nitrocellulose membrane and probed with serum from mice immunized with the 
respective protein. Serum from immunized animals bound to the recombinant protein, as well as 
protein in USA300 WCL (Figure 5). The differences seen in the size of the recombinant protein 
vs the protein recognized in WCL may be due to different glycosylation of the recombinant 
protein when expressed in E. coli. Additionally, ELISA data showed that immunized mice had 
endpoint dilution titers approaching 106 ELISA units (data not shown). These data indicate that 
immunization with recombinant protein is able to produce high titers of antibodies that recognize 
not only the recombinant protein but also protein from S. aureus.  
 
46 
 
 
 
Figure 5. Western Blot Using Serum From Mice Immunized with Recombinant Protein. 
2μg of recombinant protein was ran alongside 2μg of USA300 WCL on a 15% polyacrylamide 
gel. After transferring to nitrocellulose the membrane was immunoblotted for ClfA (A), SdrD 
(B), SdrE (C) or FnBPA (D) using serum from mice immunized with the respective recombinant 
protein.  
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Recombinant Proteins Contain T Cell Epitopes and Induce an IL-17 Response Following 
Restimulation of Splenocytes 
 Several studies have shown IL-17 to be critical for protecting mice and humans against S. 
aureus SSTIs, thus a protective vaccine will likely need to generate memory TH17 cells against 
S. aureus antigens (Cho et al. 2010; Puel et al. 2011). I therefore sought to confirm that the 
recombinant proteins I used to generate Ad vaccine vectors contain T cell epitopes and are 
capable of eliciting a TH17 response. To do this, I obtained splenocytes from mice that had been 
intradermally infected with the MRSA strains USA300 or SA113. I stimulated splenocytes with 
either USA300 whole cell extract (WCE) or recombinant proteins for 42 hours, then measured 
the number of IL-17 producing cells by ELISPOT (Figure 6).  
 Mice inoculated with MRSA demonstrated IL-17 responses to WCE, as well as to ClfA 
and SdrE recombinant proteins that was significantly greater than the response seen in naïve 
mice. Furthermore, recombinant proteins from the USA300 strain were able to induce an IL-17 
response in mice that had been previously infected with the SA113 S. aureus strain. Our lab has 
also generated data showing that humans with a history of S. aureus infection generate an IFNγ 
and IL-17 response to domains from recombinant ClfA, SdrD, SdrE and FnBPA (data not 
shown).  
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Figure 6. IL-17 Response to S. aureus Antigens. C57BL/6 mice were inoculated intradermally 
with 106 CFU of MRSA strains USA300 or SA113. 10 days later splenocytes were harvested and 
were stimulated with WCE or recombinant purified ClfAhis or SdrEhis. After 42 hours of 
stimulation the number of IL-17 producing cells was determined by ELISPOT. *p < 0.05 
 
Transgenes are Expressed in 2935 Cells Following Infection with Ad5ClfA or Ad5SdrD 
 Due to the potent T cell adjuvancy associated with Ad vectors, I hypothesized that a 
vaccine comprised of Ad vectors expressing S. aureus antigens would provide protection against 
infection. I generated Ad vectors containing domains from the S. aureus surface adhesion 
proteins ClfA or SdrD as transgenes. To confirm that ClfA and SdrD are expressed in cells 
following infection with Ad5ClfA or Ad5SdrD I performed western blots using Ad5ClfA or 
Ad5SdrD infected cell lysate.  I electrophoresed cell lysates from infected cells alongside cell 
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lysates from mock-infected cells on a polyacrylamide gel and then transferred proteins onto a 
nitrocellulose membrane. I then immunoblotted for ClfA or SdrD using serum from ClfA or 
SdrD immunized mice. Bands corresponding to ClfA and SdrD were detected in lanes containing 
cell lysates from Ad5ClfA or Ad5SdrD infected cells, confirming that the transgenes are 
expressed during Ad infection of 2935 cells (Figure 7).  Again, the difference in size of 
recombinant proteins express in e. coli compared to the proteins expressed in mammalian cells is 
likely due to glycosylation of the proteins expressed in e coli.  
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Figure 7. Immunoblot to Detect Transgene Expression in Ad5ClfA and Ad5SdrD Infected 
Cells. Cell lysates from Ad5ClfA (A) or Ad5SdrD (B) infected cells were subjected to SDS-
PAGE, then transferred onto nitrocellulose membranes. Membranes were immunoblotted for 
either ClfA (A) or SdrD (B) using serum from mice immunized with the respective recombinant 
protein. Recombinant ClfAhis or SdrDhis were ran as positive controls. Mock infected cell 
lysates served as a negative control for transgene expression. Membranes were also blotted for 
Actin which served as a loading control.  
 
Immune Response to Ad5ClfA Immunization 
 For Ad5ClfA to be an effective vaccine candidate it will need to elicit both T and B cell 
responses against ClfA. Numerous studies have shown that TH17 cells and IL-17 are important 
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mediators of vaccine induced protection. While an IL-17 response has been shown to be 
protective in a variety of infection models, it is particularly important in protecting against 
cutaneous infection (Archer, Harro, and Shirtliff 2013; Cho et al. 2010). Additionally, a number 
of studies have shown that TH1 cells and the associated production of IFNγ are required for 
vaccine mediated protection during invasive infections (Brown et al. 2015; Lin et al. 2009). 
Given that Ad vectors potently induce T cell responses, I hypothesized that Ad vaccine vectors 
would induce both IL-17 and IFNγ memory responses to vaccine antigens following 
immunization. I also hypothesized that Ad vaccine vectors would induce greater IL-17 and IFNγ 
responses compared to protein in Alum immunization, which is associated with a more dominant 
TH2 response. 
 To assess the immune response to ClfA following either protein or Ad5ClfA 
immunization, I intramuscularly immunized C57BL/6 mice with either 109 vp of Ad5ClfA or 
2μg of recombinant purified ClfAhis. I harvested the spleens 10 days post immunization, and 
restimulated splenocytes with recombinant ClfAhis for 24 hours (IFNγ) or 5 days (IL-17). 
Following restimulation, I determined the levels of IL-17 and IFNγ in the supernatants by 
ELISA. Both ClfAhis and Ad5ClfA immunization induced an IL-17 response to ClfA, however 
the IL-17 response induced by Ad5ClfA immunization was significantly greater than the 
response induced by immunization with ClfAhis in Alum (Figure 8A). Additionally, Ad5ClfA 
immunization induced an IFNγ response to ClfA that was not seen in protein immunized mice 
(Figure 8B).  
 While effective T cell responses to vaccine antigens appear to be the most important 
biomarker for protection, a B cell response to vaccine antigens may also be important. During 
infection, antibodies neutralize toxins and bind to the bacterial surface, triggering activation of 
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the classical complement pathway. Additionally, IgG antibodies bound to the bacterial surface 
mediate phagocytosis of S. aureus by phagocytes through interactions with Fcγ receptors 
(FcγRs). Given the potential functionality of antibodies in mediating bacterial clearance, I 
wanted to confirm that immunization with Ad vaccine vectors induced anti-ClfA antibodies. It is 
known that the different IgG isotypes have differing affinities for antigen and FcγRs, and 
therefore have differing abilities to mediate effector functions such as opsonophagocytosis and 
complement dependent cytotoxicity (CDC). Therefore, I also wanted to determine the istoypes of 
IgG antibodies generated in response to immunization. 
 To determine anti-ClfA antibody titers I obtained serum from mice immunized with 
either Ad5ClfA, or ClfAhis in Alum. I used the serum to perform ELISAs to determine endpoint 
dilution titers to ClfAhis, as well as to determine the IgG isotype response to ClfAhis. 
Immunization with Ad5ClfA induced a strong antibody response against ClfAhis, although 
endpoint dilution titers were reduced compared to ClfAhis+Alum immunization (Figure 8C). 
Serum from ClfAhis+Alum immunized animals contained anti-ClfA antibodies that were 
predominantly IgG1, whereas immunization with Ad5ClfA induced predominantly IgG2b and 
IgG2c istoypes (Figure 8D).  
53 
 
 
 
Figure 8. Immune Response to ClfA Following Ad5ClfA or ClfAhis Immunization. (A & B) 
C57BL/6 mice were intramuscularly immunized with 109 vp of Ad5ClfA, 2μ ClfAhis in Alum, 
or PBS. 10 days post immunization splenocytes were harvested and stimulated with recombinant 
purified ClfAhis. 24 hours (IFNγ) or 5 days (IL-17) later IFNγ (B) and IL-17 (A) levels in the 
supernatants were determined by ELISA. (C & D) Serum samples were collected from the mice 
in the above experiment. Pooled antibody titers to ClfA were determined by endpoint dilution 
assays (C). Antibody titer was determined by the highest dilution at which the absorbance value 
differed significantly from those of negative controls. (D) Anti-ClfA IgG isotypes were 
determined by ELISA and isotype response was determined based on the absorbance at 
OD450nm. *p<0.05 
 
Antibodies Generated Following Ad5ClfA or ClfAhis Immunization Bind to S. aureus 
  Anti-ClfA antibodies are generated in response to both Ad5ClfA and ClfAhis+Alum 
immunization. My previous data shows that these antibodies bind to recombinant purified 
ClfAhis, however that does not mean that the antibodies will recognize full length ClfA on the 
surface of S. aureus. For antibodies generated in response to Ad5ClfA immunization to be 
protective they need to be able to recognize ClfA expressed from S. aureus so that they can  
mediate functions such as opsonophagocytosis and CDC during infection.  
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 To determine if antibodies raised following Ad5ClfA or ClfAhis+Alum immunization 
can bind to ClfA on S. aureus I performed immunofluorescence microscopy. I struck S. aureus 
cultures onto glass coverslips and incubated them with serum from either naïve mice, or mice 
immunized with Ad5ClfA or ClfAhis+Alum. I used an Alexa Flor 568-conjugated anti-mouse-
IgG secondary antibody to detect anti-ClfA antibodies, and counterstained with DAPI. Serum 
from naïve mice did not show any binding of mouse antibodies to the bacteria; however serum 
from Ad5ClfA or ClfAhis immunized animals both contain antibodies that bind to S. aureus 
(Figure 9).  
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Figure 9. IFA of S. aureus Incubated with Serum from Immunized Mice. S. aureus cultures 
were grown overnight, washed with sterile PBS, and fixed onto glass coverslips. Cells were then 
incubated overnight with mouse serum (1:100 dilution in PBS) from naïve mice, or from mice 
immunized with Ad5ClfA or Clfahis+Alum. Cells were washed with sterile PBS then incubated 
with an Alexa Flor 568-conjugated anti-mouse-IgG secondary antibody and counterstained with 
DAPI. Coverslips were mounted on glass slides and images were acquired using a confocal 
microscope.  
 
Ad5ClfA/Ad5SdrD Immunization Provides Protection from Cutaneous MRSA Infection 
 Data implicate IL-17 and TH17 cells as having an important role in protecting against 
cutaneous S. aureus infection (Archer, Harro, and Shirtliff 2013; Cho et al. 2010; Miller and Cho 
2011). Given the ability of Ad vectors to activate T cell subsets, I hypothesized that 
immunization with Ad vectors expressing the adhesion domains from the S. aureus proteins ClfA 
and SdrD would provide protection from cutaneous MRSA infection by eliciting enhanced 
56 
 
antigen specific T cell responses. Specifically, I hypothesized that Ad vaccine vectors would 
provide enhanced protection by inducing a more potent TH17 and IL-17 response to vaccine 
antigens. I further hypothesized that if these Ad vectors are capable of eliciting stronger TH17 
responses then they would provide better protection from cutaneous infection than protein+Alum 
immunization, which invokes a strong TH2 response (Coffman, Sher, and Seder 2010) 
 To determine whether immunization with Ad vaccine vectors could provide protection 
from cutaneous MRSA infections, I first generated Ad5 vectors expressing the ligand binding 
domains from either ClfA or SdrD as transgenes. Mice were intramuscularly immunized with 109 
particles each of Ad5ClfA and Ad5SdrD. Protein-immunized mice were immunized with 2μg 
each of ClfAhis, SdrDhis, SdrEhis, and FnBPAhis. Mice injected with PBS were used as an 
unimmunized control, and mice immunized with 2x109 vp of Ad5gfp served as a vector control.  
 28 days post immunization mice were challenged by intradermal inoculation at four sites 
with 2x106 CFU/site of the USA300 strain of MRSA. On day six post challenge mice were 
sacrificed and bacterial load in the wounds was determined by plating dilutions of wound 
homogenates onto Tryptic Soy Agar (TSA) plates. Measurements of the wound sizes were also 
obtained and used to evaluate protection. Mice immunized with Ad5ClfA/Ad5SdrD had 
significantly lower bacterial titers in the wounds than PBS and Ad5gfp immunized mice, and had 
reduced titers compared to protein-immunized mice that were approaching significance (Figure 
10A). In addition, Ad5CflA/Ad5SdrD immunized mice had significantly reduced wound sizes 
compared to PBS and Ad5gfp immunized mice (Figure 10B-C). To determine the limit of 
vaccine efficacy, I challenged mice with various doses of USA300 and assessed bacterial load in 
the wounds as a measure of protection. The data obtained indicate that Ad5ClfA/Ad5SdrD does 
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not afford protection against high doses of bacteria, but that at challenge doses in the range of 
106 CFU/site it is able to provide protection (Figure 10D). 
 
 
Figure 10. Effects of Ad5ClfA/Ad5SdrD Immunization on Cutaneous MRSA Challenge. 
C57BL/6 mice were intramuscularly immunized with 109 vp/mouse of Ad5ClfA and 109 
vp/mouse of Ad5SdrD. Alternatively, mice were immunized with 2μg each of ClfAhis, SdrDhis, 
SdrEhis and FnBPAhis, 2x109 vp of Ad5gfp, or PBS, with 9-12 mice per group. 28 days post 
immunization mice were intradermally challenged with 2x106 CFU/site on 4 sites on their back. 
Six days post challenge mice were sacrificed and the bacterial load in the wound (A) and average 
wound sizes (B) were determined. (C) Representative wound images from the experiments 
described above. (D) To determine vaccine efficacy, C57BL/6 mice were immunized as 
described above. 28 days post immunization mice were challenged with the indicated CFU on 4 
sites on their back. Six days post challenge mice were sacrificed and the bacterial load in the 
wounds was determined as a measure of protection. *p<0.05 
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Wounds from Ad5ClfA/Ad5SdrD Immunized Animals Exhibit Enhanced Expression of 
mRNA Encoding for IL-17 and Neutrophil Chemokines 
 My data suggest that immunization with Ad vectors expressing S. aureus antigens 
provides protection against cutaneous MRSA challenge. Numerous studies have shown IL-17 to 
be required for vaccine mediated protection, particularly in response to cutaneous infections 
(Narita et al. 2010; Yeaman et al. 2014).  Data from Ad5ClfA immunization experiments show 
that Ad5ClfA immunization induces an IL-17 response to ClfA. Therefore, I expected that 
Ad5ClfA/Ad5SdrD immunized animals would have a greater IL-17 response that would provide 
protection against challenge.   
During cutaneous S. aureus infections IL-17 stimulates keratinocytes to produce 
chemokines and adhesion molecules, including CXCL1, CXCL2 and CXCL5, that recruit 
neutrophils to the infection site (Herjan et al. 2013; Miller and Cho 2011). I expected that if there 
was an increased IL-17 response in Ad5ClfA/Ad5SdrD immunized mice then there would also 
be greater expression of neutrophil recruiting chemokines. Neutrophils are crucial in the 
clearance of S. aureus, therefore I hypothesized that an IL-17 mediated increase in neutrophil 
recruitment may be one mechanism of vaccine mediated protection. 
To determine whether there was increased expression of mRNA encoding for IL-17 and 
neutrophil recruiting chemokines in the wounds of Ad5ClfA/Ad5SdrD immunized animals I 
isolated RNA from wound samples and performed RT-qPCR to quantify mRNA expression. 
Ad5ClfA/Ad5SdrD immunized animals had greater IL-17 mRNA expression than either PBS or 
protein immunized animals (Figure 11). Compared to both PBS and protein immunized animals 
Ad5ClfA/Ad5SdrD animals also had increased expression of CXCL1 and CXCL5 mRNA, 
consistent with the increase in IL-17 mRNA expression (Figure 11). Both Ad and protein-
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immunized animals had increased expression of CXCL2 mRNA compared to PBS immunized 
animals. These data indicate that a possible mechanism of Ad5ClfA/Ad5SdrD mediated 
protection may be through IL-17 mediated neutrophil recruitment to sites of infection. 
 
 
Figure 11. mRNA Expression in the Wound Following USA300 Challenge. C57BL/6 mice 
were intramuscularly immunized with 109 vp of Ad5ClfA and 109 vp of Ad5SdrD, 2μg each of 
ClfAhis, SdrDhis, SdrEhis and FnBPAhis, or PBS. 28 days post immunization mice were 
intradermally challenged with 2x106 CFU on 4 sites on their back. Six days post challenge mice 
were sacrificed and RNA was isolated from wound samples. IL-17, CXCL1, CXCL2, and 
CXCL5 mRNA expression from pooled wound RNA samples were determined by quantitative 
RT-PCR using the 2-∆∆CT method. 
 
Ad5ClfA/Ad5SdrD Immunized Mice Generate High Titer Anti-ClfA Antibodies Following 
USA300 Challenge That Have a Distinct IgG Profile Compared to Protein Immunization 
 Although vaccine strategies aimed solely at generating antibody responses to S. aureus 
antigens have largely been unsuccessful, antibodies generated in conjunction with a strong T cell 
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response may be important in Ad5ClfA/Ad5SdrD vaccine mediated protection. Following 
production of cytokines from activated T cells, neutrophils are recruited to sites of cutaneous 
infection. Neutrophils are then able to mediate clearance of bacteria through a variety of 
mechanisms, including antibody mediated phagocytosis and killing of opsonized bacteria (Segal 
2005). In this way antibodies can help facilitate bacterial clearance and may be involved in 
Ad5ClfA/Ad5SdrD vaccine mediated protection.  
 To determine the antibody response to vaccine antigens following immunization and 
challenge, I collected serum from mice in the above described immunization and challenge 
experiments and determined the endpoint dilution titers by ELISA (Figure 12A). I found that, as 
expected, protein in Alum immunized animals had robust antibody responses to all four vaccine 
antigens. Animals immunized with PBS or Ad5gfp did not have detectable antibody responses to 
ClfA, SdrD, SdrE, or FnBPA. Importantly, immunization with Ad5ClfA/Ad5SdrD yielded 
antibody titers against ClfA that were comparable to those elicited by immunization with the 
purified protein.  
 While protein and Ad immunized animals show comparable levels of anti-ClfA 
antibodies following USA300 challenge, the isotypes of anti-ClfA antibodies may differ between 
the two groups of animals. Indeed, data from my immunization studies show that Ad5ClfA 
immunization induces antibodies that are predominantly IgG2b and IgG2c whereas antibodies 
generated in response to immunization with recombinant protein in Alum are predominantly 
IgG1. IgG isotypes have differing capacities to mediate antibody effector functions, therefore 
differences in the isotypes of antibodies elicited could account for some of the difference in 
protective capacity seen between protein and Ad immunized animals.  
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 I next asked whether immunization with Ad5ClfA/Ad5SdrD elicited a different profile of 
anti-ClfA IgG isotypes following USA300 challenge than immunization with protein in Alum. 
Consistent with the IgG profiles seen in data from immunization studies, protein in Alum 
immunization induced mainly IgG1 antibodies while Ad5ClfA/Ad5SdrD immunization induced 
anti-ClfA antibodies that were predominantly IgG2b and IgG2c (Figure 12B). These data 
indicate that while the total levels of anti-ClfA IgG are comparable between protein and 
Ad5ClfA/Ad5SdrD immunized animals, the isotype profile of the IgG antibodies are dependent 
on whether the vaccine antigen is delivered via an alum or Ad adjuvant. 
62 
 
 
 
Figure 12. Antibody Response to ClfA Following USA300 Challenge. C57BL/6 mice were 
intramuscularly immunized with 109 vp of Ad5ClfA and 109 vp of Ad5SdrD, 2μg each of 
ClfAhis, SdrDhis, SdrEhis, and FnBPAhis, 2x109 vp of Ad5gfp, or PBS. 28 days post 
immunization mice were intradermally challenged with 2x106 CFU on 4 sites on their back. Six 
days post challenge mice were sacrificed and serum was collected. (A) Total IgG antibody titers 
against ClfA, SdrD, SdrE, and FnBPA were determined by endpoint dilution assays using pooled 
serum samples. Antibody titer was determined by the highest dilution at which the absorbance 
value differed significantly from those of negative controls. (B) Anti-ClfA IgG isotypes were 
determined by ELISA and isotype response was determined based on absorbance at OD450nm. 
*p<0.05 
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Serum from Ad5ClfA/Ad5SdrD Immunized Mice Mediates Uptake of USA300 by 
Macrophages 
 Data from my immunization experiments, as well as immunization/challenge 
experiments, show that anti-ClfA IgG isotypes in Ad5ClfA/Ad5SdrD immunized animals consist 
mainly of IgG2 isotypes. This is in contrast to protein immunized mice, which develop anti-ClfA 
IgGs that are mainly comprised of IgG1. In mice IgG2 isotypes have the highest binding affinity 
to activating FCγRs, whereas IgG1 isotypes have relatively low binding affinity to FCγRs 
(Jonsson and Daeron 2012; Stewart et al. 2014). Binding of high levels of antigen bound IgGs 
activates FCγRs and leads to FCγR mediated effector functions such as ADCC and antibody 
mediated opsonization by phagocytic cells. Following internalization of bacteria, phagocytic 
cells mediate bacterial killing through a variety of mechanisms. Therefore, I hypothesized that 
one mechanism of Ad5ClfA/Ad5SdrD vaccine mediated protection may be enhanced IgG2 
mediated opsonization of bacteria.  
 To determine if serum from Ad5ClfA/Ad5SdrD immunized animals mediated bacterial 
uptake more efficiently than serum from protein, vector control, or PBS immunized animals I 
performed OPAs using a macrophage cell line and serum from mice in the previously described 
immunization and challenge experiments. Serum from Ad5ClfA/Ad5SdrD immunized mice 
mediated increased uptake of opsonized bacteria by RAW264.7 macrophages compared to serum 
from PBS, Ad5gfp or protein immunized animals (Figure 13). This suggests that a possible 
mechanism of vaccine mediated protection may be through enhanced opsonophagocytosis of S. 
aureus.  
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Figure 13. Serum Mediated Opsonophagocytic Activity. Pooled serum was obtained from 
animals in the previously described immunization and challenge experiments. Pooled serum was 
diluted 1:100 and incubated with USA300 for 30 minutes. Antibody coated bacteria were 
incubated for 30 minutes with RAW264.7 cells, then treated with 2μg/mL gentamycin and the 
total number of opsonized bacteria was determined by plating dilutions of the lysed RAW264.7 
cells onto tryptic soy agar (TSA). Total bacteria taken up was normalized to the number of 
bacteria added to the RAW264.7 culture at time 0 minutes. *p<0.05 
 
Ad5 Vectors with Enhanced Inflammasome Activation Elicit Enhanced IL-17 and IFNγ 
 Data from infection models and vaccine studies suggest that TH1 and TH17 cells, as well 
their associated cytokines IFNγ and IL-17, are important mediators of protection against S. 
aureus infection. My data show that Ad5 vectors expressing S. aureus antigens are able to 
provide protection against cutaneous MRSA infection. I hypothesized that modified Ad vectors, 
capable of eliciting increased TH1 and TH17 responses may provide even greater protection 
against MRSA challenge.  
 Cytokines IL-1 and IL-18, which are secreted following inflammasome activation, 
drive differentiation of TH17 and TH1 cells, respectively. Therefore, a modified Ad5 vector with 
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increased inflammasome activation may be able to more potently induce TH1 and TH17 T cell 
subsets. Our lab has previously generated Ad vectors with enhanced inflammasome activation 
due to the appendage of the 35-C terminal amino acids from FliC onto the Ad capsid protein pIX 
(Ad5PF). Given that Ad5PF shows augmented inflammasome activation compared to Ad5 
vectors, I expected that Ad5PF would also induce greater TH1 and TH17 responses. To determine 
whether Ad5PF vectors are able to induce stronger TH1 and TH17 responses to vaccine antigens 
compared to unmodified Ad5 vectors I used Ad5 vectors expressing GFP as a model transgene.  
I immunized BALB/C mice with Ad5gfp or the modified vector Ad5PFgfp and harvested 
splenocytes 10 days post immunization. I re-stimulated splenocytes with GFP, or Ad5 empty 
capsid to determine the immune response to the vector, and determined IL-17 and IFNγ levels in 
the supernatant by ELISA. As expected, splenocytes from animals immunized with Ad5PFgfp 
showed significantly more production of IFNγ and IL-17 in response to GFP than the unmodified 
vector Ad5gfp (Figure 14). The IFNγ and IL-17 response to the vector was also increased in 
Ad5PFgfp immunized animals. 
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Figure 14. T Cell Response to Ad5PFgfp Immunization. BALB/C mice were intramuscularly 
immunized with 1010 vp of Ad5gfp or Ad5PFgfp. Ten days post immunization mice were 
sacrificed and splenocytes were harvested. Splenocytes were restimulated with GFP or Ad5 
empty capsid. 24 hours (IFNγ) or five days (IL-17) post restimulation the supernatant was 
collected and the amount of IL-17 (A) and IFNγ (B) present was determined by ELISA. *p<0.05 
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Ad5PFgfp Immunized Mice Show Increased Expression of IL-17, IFNγ, and IL-21 mRNA 
 Splenocytes from Ad5PFgfp immunized mice show increased production of IL-17 and 
IFNγ in response to restimulation with GFP. This suggests that Ad5PFgfp immunization induces 
more potent T cell responses to vaccine antigens than unmodified Ad5 vectors. To further 
evaluate the effects of Ad5PFgfp immunization on T cell activation I also looked at expression 
of T cell cytokines in the draining lymph nodes from Ad5PFgfp and Ad5gfp immunized mice. If 
Ad5PFgfp induces greater T cell activation then I expected to see increased expression of IL-17 
and IFNγ in the draining lymph nodes, consistent with the increased responses seen in 
splenocytes. I would also expect to see increased expression of IL-21, which is predominantly 
produced by CD4+ T cells including T follicular helper (TFH) and TH17 cells (Mitsdoerffer et al. 
2010). Lymph nodes from animals immunized with Ad5PFgfp had greater expression of IL-17, 
IFNγ and IL-21 mRNA than Ad5gfp immunized animals (Figure 15), supporting the hypothesis 
that the pIXFliC vector is able to enhance activation of T cells.  
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Figure 15. mRNA Expression in the Lymph Node of Ad5PFgfp and Ad5gfp Immunized 
Mice. BALB/C mice were intramuscularly immunized with 1010 vp of Ad5gfp or Ad5PFgfp. 
Ten days post immunization mice were sacrificed and the draining lymph nodes were harvested. 
IL-17, IFNγ, and IL-21 mRNA expression in the draining lymph nodes were determined by 
quantitative RT-PCR using the 2-∆∆CT method. 
 
Ad5PFgfp Immunization Provides Protection Against S. aureus Challenge 
 Ad5PFgfp immunization induces increased IL-17 responses to vaccine antigens 
compared to immunization with Ad5gfp. Given the importance of IL-17 in protecting against 
cutaneous infections, I hypothesized that immunization with the FliC expressing vector would 
provide protection against cutaneous infection. Furthermore, since Ad5PF vectors induce a 
stronger IL-17 response I expected that Ad5PF immunization would provide greater protection 
against cutaneous infection than immunization with unmodified Ad5 vectors.  
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 As Ad5PFgfp and Ad5gfp viruses had been previously purified I sought to determine 
whether immunization with these vectors could provide protection against cutaneous S. aureus 
infection.  Although these vectors do not express S. aureus antigens, I hypothesized that the 
augmented IL-17 response to the vector could induce a protective immune response. I also used 
S. aureus strains expressing GFP, with the rationale that the anti-GFP response may still afford 
protection by further augmenting the IL-17 response at the site of infection. In this way the anti-
GFP response could mimic the response seen from vectors expressing S. aureus antigens. 
 I first asked whether Ad5PFgfp could provide protection against a less virulent, 
methicillin sensitive, S. aureus strain. Ad5PFgfp and Ad5gfp immunized mice were challenged 
with the RN4220gfp strain of S. aureus and protection was assessed by determining the wound 
bacterial loads. PBS immunized mice were used as an unimmunized control. I found that while 
animals immunized with Ad5gfp or PBS had comparable bacterial titers in their wounds, animals 
immunized with Ad5PFgfp had significantly lower bacterial titers in their wounds compared to 
PBS immunized animals (Figure 16A). The reduction in bacterial load corresponded to an 
increased IL-17 response by splenocytes (Figure 16B).  
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Figure 16. Effects of Ad5PFgfp Immunization on Cutaneous Challenge with RN4220gfp. 
C57BL/6 mice were intramuscularly immunized with 1010 vp of Ad5gfp or Ad5PFgfp. PBS 
immunized mice were used as an unimmunized control. 28 days post immunization mice were 
intradermally challenged with 2x106 CFU of RN4220gfp on 4 sites on their back. Three days 
post challenge mice were sacrificed and bacterial load in the wound was determined (A). (B) 
Splenocytes were restimulated with Ad5 empty capsid or GFP. Five days post restimulation the 
supernatants were collected and the amount of IL-17 present was determined by ELISA. *p<0.05 
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Since Ad5PFgfp is able to protect against cutaneous S. aureus infections with methicillin 
sensitive strains I next asked whether this protection extended to MRSA infections. To determine 
whether Ad5PFgfp immunization could provide greater protection than Ad5gfp against MRSA 
challenge I used a GFP expressing strain of USA300 to challenge mice that had previously been 
immunized with Ad5gfp or Ad5PFgfp. Mice immunized with Ad5PFgfp had significantly 
reduced bacterial load in their wounds compared to mice immunized with Ad5gfp (Figure 17A). 
Although not statistically significant, protection did correlate with an increased IL-17 response 
(Figure 17B). These data suggest that the increased IL-17 response induced by the Ad5PF vector 
is capable of providing protection against MRSA infection, and that this protection is greater 
than that afforded by unmodified Ad vectors. 
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Figure 17. Effects of Ad5PFgfp Immunization on Cutaneous Challenge with MRSA.  
BALB/C mice were intramuscularly immunized with 1010 vp of Ad5gfp or Ad5PFgfp. 35 days 
post immunization mice were intradermally challenged with 2x106 CFU of USA300gfp on 4 
sites on their back. Six days post challenge mice were sacrificed and bacterial load in the wound 
was determined (A). (B) Splenocytes were restimulated with Ad5 empty capsid or GFP. Five 
days post restimulation the supernatants were collected and the amount of IL-17 present was 
determined by ELISA. *p<0.05
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CHAPTER FOUR 
DISCUSSION 
S. aureus is a major cause of hospital and community acquired infections worldwide. 
These infections range from less serious SSTIs to invasive, life-threatening infections such as 
bacteremia, pneumonia, endocarditis, and sepsis. Treatment of these infections is becoming more 
challenging due to the rise of methicillin resistant S. aureus strains that are resistant to an 
increasing number of antibiotics. MRSA infections are associated with high rates of morbidity 
and mortality, and the treatment of these infections represent a significant financial burden. 
Development of a vaccine capable of providing protection against MRSA infections would 
significantly advance public health worldwide. Unfortunately, current vaccine strategies have 
been largely aimed at generating high titer antibody responses to vaccine antigens and have 
proven unsuccessful in clinical trials.  
My goal in this work was to use Adenovirus vectors to develop a vaccine that could 
provide protection against cutaneous MRSA infections, and to begin to explore the mechanism 
of vaccine mediated protection. I first wanted to determine whether Ad vectors expressing S. 
aureus antigens could protect against cutaneous challenge in mice. I next asked whether Ad 
vectors that more potently activate the inflammasome could provide enhanced protection against 
MRSA challenge due to their ability to induce greater activation of T cells 
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Immunogenicity of Recombinant S. aureus Proteins 
 The majority of S. aureus vaccine candidates have consisted of active immunization 
approaches using proteins antigens, and have focused on generating high titer functional 
antibodies against antigen (Giersing et al. 2016). Many of these candidates have shown efficacy 
in mouse models, however this has not translated to success in humans. Failure of past vaccines 
has been attributed, in part, to failure to induce T cell mediated responses and functional 
antibodies. We hypothesized that Ad vectors, which are potent T cell adjuvants, would help to 
induce a strong anti-S. aureus T cell response that would provide greater protection than 
immunization with protein antigen. We further hypothesized that enhanced T cell responses 
would induce greater functional responses against S. aureus, including increased neutrophil 
recruitment and killing of opsonized bacteria and higher affinity class-switched antibodies. These 
features would overcome many of the failings seen in protein-based vaccines and could translate 
into an efficacious human vaccine.  
To evaluate the efficacy of our vaccine vectors compared to protein immunization, which 
has previously been shown to be protective in mice, we generated recombinant proteins 
containing the ligand binding domains from the S. aureus surface proteins ClfA, SdrD, SdrE, and 
FnBPA. Data from western blots and ELISAs confirm that the recombinant purified proteins 
contain B cell epitopes. Antibodies generated against the recombinant proteins bind to protein in 
S. aureus WLC, and IFA data show that serum from ClfA immunized mice contain antibodies 
that bind to the surface of S. aureus. These data suggest that the recombinant proteins are either 
folded correctly or that the antibodies generated are not conformation dependent.  
Emerging data suggest that T cells, and TH17 cells specifically, are important mediators
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of anti-S. aureus immunity. It is therefore essential that any potential vaccine antigen contain 
high affinity T cell epitopes. Due to the importance of IL-17 and IFNγ in mediating clearance of 
S. aureus I wanted to confirm that the domains I used to construct the recombinant proteins and 
Ad vaccine vectors contained T cell epitopes capable of inducing TH17 and TH1 responses. 
ELISPOT data from mice and humans with prior S. aureus infections show that re-stimulation of 
splenocytes with recombinant proteins induces an IL-17 and IFNγ response. This suggests that 
these antigens are capable of inducing a memory TH17 and TH1 response. Additionally, IL-17 
responses to recombinant proteins from USA300 were seen in animals that had previously been 
infected with the SA113 strain, suggesting these antigens can elicit cross-reactive immunity 
against numerous different strains of S. aureus – a requirement for any potential vaccine antigen. 
Anti-ClfA Immunity Induced by Ad5ClfA Immunization 
 For Ad vector vaccines for MRSA to be effective they will likely need to induce both T 
and B cell responses to vaccine antigens. CD4+ T cell responses have been shown to be required 
for a number of vaccine candidates that have shown efficacy in mice, and deficiencies in T cell 
subsets are associated with increased risk for S. aureus infections (Lin et al. 2009; Yeaman et al. 
2014). While a B cell response alone does not appear to be sufficient to provide protection 
against S. aureus infections, antibodies will likely be important mediators of bacterial clearance 
following T cell induced recruitment of phagocytic cells.  
 Both TH1 and TH17 responses, as well as their archetypal cytokines IFNγ and IL-17, have 
been shown to be critical for vaccine mediated protection in a variety to S. aureus infection 
models (Joshi et al. 2012; Lin et al. 2009; Narita et al. 2010). ELISA data from my immunization 
experiments show that Ad5CflA immunization is capable of eliciting IL-17 and IFNγ responses 
to ClfA, suggesting that immunization induces TH17 and TH1 responses. I expect that the 
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majority of activated antigen-specific cells expressing these cytokines in response to ClfA will 
be CD4+ TH1 and TH17, however it is possible that other cell types are producing these 
cytokines. A number of cell types, including CD8+ and γδ T cells, have also been shown to 
produce IL-17 and IFNγ. It is known that Ad potently induces CD8+ T cells, so it is possible that 
the IL-17 and IFNγ responses are coming from this cell type rather than CD4+ T cells. In the 
future intracellular cytokine staining and FACs could be used to determine the phenotype of cells 
expressing IL-17 or IFNγ in response to vaccine antigen.  
 Immunization with S. aureus surface proteins has shown limited protection in mouse 
models, and protection following protein immunization is thought to depend on IL-17 and IFNγ 
production from CD4+ T cells (Lin et al. 2009; Narita et al. 2010). Given that Ad vectors more 
potently activate T cell responses compared to protein in Alum immunization I expected that an 
Ad vector vaccine would provide greater protection against MRSA challenge compared to 
protein immunization due to increased T cell responses. In support of this theory, ELISA data 
showed that Ad5ClfA immunization induced significantly more IL-17 and IFNγ compared to 
ClfAhis immunization. In fact, ClfAhis immunization failed to induce IFNγ responses to ClfA 
that were above the levels seen in PBS immunized controls.  
 Although anti-ClfA antibody titers are significantly higher in protein immunized mice, 
Ad5ClfA immunization does induce a strong antibody response to ClfA. Antibodies induced 
following Ad5ClfA immunization not only recognize recombinant protein, but also bind to 
whole S. aureus bacterial as shown by our IFA data. Furthermore, Ad5ClfA immunization 
induces a different anti-ClfA IgG profile than does protein immunization. Anti-ClfA antibodies 
in protein immunized mice were primarily IgG1, whereas antibodies in Ad5ClfA immunized 
mice were composed of IgG2b and IgG2c isotypes. This has important implications for vaccine 
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development, as it is known that mouse IgG2 isotypes have the highest binding affinities to 
FCγRs and would likely be more efficient at mediating bacterial clearance via 
opsonophagocytosis than IgG1 antibodies (Stewart et al. 2014). To determine whether Ad5ClfA 
induced antibodies are actually more functional in mediating opsonophagocytosis than antibodies 
from protein immunized mice OPAs could be performed.  
 To date I have purified both Ad5ClfA and Ad5SdrD. In the future it would be of value to 
perform immunization experiments using Ad5SdrD to determine whether we see a similar 
immune response to SdrD as we do to ClfA following Ad vector immunization. Studies suggest 
that immunization with ClfA induces antigen specific IL-17 responses, however other S. aureus 
surface adhesion proteins have not been extensively studied and therefore much less is known 
about the immunogenicity of SdrD, SdrE and FnBPA as vaccine antigens (Narita et al. 2010).  
Ad5ClfA/Ad5SdrD Mediated Protection Against MRSA 
 Immunization with Ad5ClfA/Ad5SdrD was protective against cutaneous MRSA 
challenge. Compared to PBS and vector control immunized mice, Ad5ClfA/Ad5SdrD 
immunized mice had significantly reduced wound sizes and bacterial loads. Additionally, Ad 
immunized mice had reduced wound size and bacterial load compared to protein immunized 
mice. The majority of vaccine candidates to date have consisted of active immunization with 
protein antigen or passive immunization with monoclonal antibodies (Giersing et al. 2016). 
Unfortunately, none of these vaccine candidates have shown success in clinical trials. Our data 
suggest that Ad vectors represent a novel S. aureus vaccine approach that could be used to 
generate a vaccine for cutaneous MRSA infections. 
 Our vaccine efficacy data show that Ad vectors expressing S. aureus antigens are 
protective at challenge doses in the range of 106 CFU, but not at CFUs in the range of 107. While 
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a vaccine that is capable of protecting against the highest bacterial load would be ideal, a vaccine 
capable of protecting against 106 CFU would still be a significant public health achievement. 
Previous studies have shown that immunization with multiple antigens affords greater protection 
than immunization with individual antigens (Zuo et al. 2013), therefore co-immunization with 
Ad vectors expressing additional antigens, such as SdrE and FnBPA could enhance the 
protective efficacy of our vaccine. Additionally, booster immunizations may afford additional 
protective immunity. If Ad5ClfA/Ad5SdrD is to be further explored as a possible vaccine 
candidate it will need to be protective against not only USA300, but a wide variety of S. aureus 
strains. It will therefore be important to determine whether Ad5ClfA/Ad5SdrD immunization is 
able to afford protection against additional MRSA strains.   
 Cutaneous S. aureus infections are a leading cause of skin and soft tissue infections 
(SSTIs) worldwide, and these infections have the potential to go on to cause invasive and life-
threatening infections. Development of a vaccine that can protect against cutaneous infections 
would be extremely beneficial not only in preventing SSTIs, but also in preventing more 
invasive infections that result from cutaneous infections. While IL-17 is commonly associated 
with protection against cutaneous infection it has also been shown, along with TH1 cells and 
IFNγ, to provide protection in murine bacteremia models (Lin et al. 2009; Narita et al. 2010). It 
is therefore possible that the T cell responses induced by Ad5ClfA/Ad5SdrD immunization could 
also provide protection against other types of S. aureus infection. It would be worthwhile to 
perform additional immunization challenge experiments using models such as bacteremia or 
endocarditis to determine whether Ad vector vaccines can protect against these types of 
infections in addition to cutaneous infections. 
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 mRNA expression of IL-17 is increased in the wounds of Ad5ClfA/Ad5SdrD immunized 
mice and correlates with protection from cutaneous MRSA infection. Ad5ClfA immunization 
generates an IL-17 response to ClfA, therefore it is likely that the increased IL-17 expression in 
the wounds of Ad5ClfA/Ad5SdrD immunized mice is due to vaccine mediated enhancement of 
IL-17 responses to ClfA and SdrD. Further studies would be needed to confirm whether the 
increased IL-17 expression is due to increased IL-17 responses to vaccine antigens and if this 
correlates with increased IL-17 production in the wounds. To understand the mechanisms 
involved in vaccine mediated protection it will be important to determine the cellular source of 
the increased IL-17 response. As TH17 cells are a major source of IL-17, I expect that 
Ad5ClfA/Ad5SdrD immunization will have generated memory TH17 cells to ClfA and SdrD that 
are responsible for the increased IL-17 response. It is also possible that CD8+ T cells or γδ T 
cells, which are abundant in the skin, are responsible for the increased production of IL-17 in 
Ad5ClfA/Ad5SdrD immunized animals.  
Given that IL-17 is known to stimulate production of neutrophil recruiting chemokines, it 
is not surprising that the expression of CXCL1 and CXCL5 are also increased in the wounds of 
Ad5ClfA/Ad5SdrD mice. I expect that immunohistochemistry or FACS would show increased 
neutrophil recruitment to the wounds of Ad5ClfA/Ad5SdrD animals, consistent with the 
increased expression of these neutrophil recruiting chemokines. Neutrophils are critical for 
immunity against S. aureus infections, therefore I expect that a key mechanism of vaccine 
mediated protection is enhanced neutrophil mediated bacterial clearance due to increased IL-17 
and downstream chemokine production.  
Consistent with the IgG profiles seen following immunization, MRSA infected mice that 
have been previously immunized with Ad5ClfA/Ad5SdrD contain anti-ClfA antibodies that are 
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primarily IgG2b and IgG2c. This is in contrast to mice immunized with recombinant proteins, 
which contain mainly IgG1 antibodies against ClfA. IgG2 isotypes in mice are known to have 
higher binding affinity for FCγR, which I expected would result in greater uptake of bacteria by 
phagocytic cells. My OPA data show that this is indeed the case, as serum from 
Ad5ClfA/Ad5SdrD immunized mice mediates significantly greater bacterial uptake compared to 
serum from control or protein immunized mice. These data support my theory that Ad vaccine 
mediated protection involves increased bacterial clearance by neutrophils. The data further 
suggest that in addition to increased neutrophil recruitment, vaccine mediated protection may be 
due to the generation of antibodies with increased opsonophagocytic capabilities. While the OPA 
data show that serum from Ad5ClfA/Ad5SdrD immunized animals mediates greater bacterial 
uptake, additional experiments are needed to confirm that this also corresponds with killing of 
internalized bacterial.  
In our immunization and challenge experiments, mice immunized with 
Ad5ClfA/Ad5SdrD generate titers of anti-ClfA antibodies that are comparable to the titers seen 
in protein immunized mice. While protein immunized mice also generate anti-SdrD antibodies, 
no anti-SdrD antibodies were detected in Ad5ClfA/Ad5SdrD immunized mice. The immune 
response to Ad5SdrD immunization has not yet been evaluated, therefore it is possible that SdrD 
expressed from our Ad vector is not as immunogenic as ClfA. It is also possible that the 
transgene is not getting expressed properly in mice, however in vitro data show that SdrD is 
expressed following Ad5SdrD infection of 2935 cells.  
Transgene Immunity Induced by Immunization with Ad5PF Vectors 
 FliC has been used as an adjuvant both by co-administering FliC with vaccine antigens 
and by creating FliC fusion proteins with antigen. FliC has been shown to increase activation of 
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DCs, T cells and to promote B cell class switching (Bennett et al. 2015). Our lab has generated 
Ad5 vectors that display the 35 C terminal amino acids from FliC on the surface of the capsid. 
FliC activates the NLRC4 inflammasome, which can then cleave pro-IL-1 and pro-IL-18 into 
forms that are secreted from the cell. Since these cytokines are involved in directing T cell 
differentiation toward TH17 and TH1 subsets, respectively, I hypothesized that vectors displaying 
FliC would enhance the differentiation of naïve T cells into TH17 and TH1 subsets. Although 
FliC is displayed on the viral capsid and the vaccine antigen is delivered as a transgene, I 
hypothesized that the increased presence of IL-1 and IL-18 in the local milieu would enhance 
the differentiation of TH17 and TH1 subsets not only to the viral capsid but also to the transgene.   
Animals immunized with Ad5PFgfp showed significantly greater IL-17 and IFNγ 
responses than animals immunized with unmodified Ad5 (Ad5gfp). Importantly, the increased 
cytokine responses were seen not only to the viral capsid but also to the transgene GFP. These 
data show that FliC displayed on the viral capsid is able to act as an adjuvant for vaccine 
antigens delivered as transgenes. The ELISA data show increased IL-17 and IFNγ responses 
which suggest that the antigen specific TH17 and TH1 responses are increased, however it is 
possible that other cell types are responsible for the increased cytokine responses. Ad very 
potently induced CD8+ T cell responses, so it is possible that CD8+ rather than CD4+ T cells are 
responsible for the increased IL-17 and IFNγ responses that we see. In the future I could use 
FACs and intracellular cytokine staining to determine the phenotype of cells expressing IL-17 or 
IFNγ following restimulation with antigen.  
In addition to performing ELISA assays, I also measured mRNA expression in the 
draining lymph nodes of immunized animals. q-RT-PCR data support the findings from the 
ELISA assays, showing that the lymph nodes from Ad5PFgfp immunized animals have 
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increased expression of IL-17, IFNγ and IL-21 mRNA. IL-21 is produced by TH17 cells as well 
as TFH cells and plays a critical role in supporting B cell differentiation and production of high 
affinity class switched antibodies (Spolski and Leonard 2010). Therefore, it is likely that the 
Ad5PFgfp vector is able to augment both T and B cell responses to vaccine antigens and give 
rise to antibody responses that have increased effector functions. 
Ad5PF as a MRSA Vaccine Vector 
 Mice immunized with Ad5PFgfp vectors show increased TH17 and TH1 responses to 
antigens expressed as transgenes. TH17 and TH1 responses have been shown to mediate 
protection against S. aureus infection. Additionally, data from our immunization and challenge 
experiments suggest that one mechanism of Ad vector mediated protection is through increased 
IL-17 production in response to S. aureus antigens. I hypothesized that due to the ability of 
Ad5PF vectors to more potently induce T cell responses, and specifically IL-17 responses, these 
vectors would provide greater protection against MRSA infection compared to Ad5 vectors.  
 Since we have not yet purified Ad5PF vectors expressing S. aureus antigens as 
transgenes I used Ad5PF vectors expressing GFP as a model transgene to perform immunization 
and challenge experiments. To more closely mimic a vector expressing a bacterial antigen, I also 
used S. aureus strains that express GFP. In these strains GFP would not be acting as a virulence 
factor, nor would it mediate immune evasion or invasion of new tissues as ClfA does, but it 
would allow antigen specific T cells induced during immunization to encounter their antigen and 
mediate effector functions.  
 Initially, we performed challenge experiments using a non-MRSA strain of S. aureus, 
RN4220gfp. This strain is less virulent than the MRSA strain USA300 and therefore would 
allow us to more easily detect protective effects afforded by Ad5PF vectors. While neither PBS 
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nor Ad5gfp immunized animals were protected, Ad5PFgfp immunized animals had reduced 
bacterial titers in their wounds. Splenocytes from these mice showed increased IL-17 responses 
to GFP, which is consistent with the data from immunization experiments. Given the promising 
results from the RN4220gfp challenge experiments, we repeated the immunization and challenge 
experiments using USA300gfp. Again, Ad5PFgfp immunized mice had significantly reduced 
bacterial titers and increased IL-17 responses.  
These data suggest that the increased IL-17 response induced by Ad5PF vectors are 
capable of inducing an immune environment that provides greater protection against cutaneous 
infection than immunization with Ad5 vectors. In the future, Ad5PF vectors expressing MRSA 
antigens should be used to determine the ability of these vectors to provide protection against 
USA300 infection. I expect that immunization with Ad5PFClfA/Ad5PFSdrD would provide 
enhanced protection over that seen in response to Ad5ClfA/Ad5SdrD immunization. Given that 
ClfA plays a role in S. aureus pathogenesis, whereas GFP does not, I would expect that immune 
responses directed at ClfA would provide greater protection since they would likely inhibit the 
pathogenic effects of ClfA.  
If Ad5PF vectors are to be used as vaccine candidates, it will be necessary to more 
thoroughly assess the mechanisms involved in vaccine mediated protection. I hypothesize that 
these vectors are inducing greater TH17 and TH1 responses, and ELISA data showing increased 
IL-17 and IFNγ responses support this theory. However, it remains to be definitively shown that 
TH17 and TH1 cells are the cell types responsible for the increased cytokine response. Challenge 
experiments using Ad5ClfA/Ad5SdrD suggest that increased IL-17 responses mediate increased 
neutrophil recruitment and induce antibodies that are more capable of mediating 
opsonophagocytosis. Ad5PF vectors induce even greater IL-17 responses than Ad5 vectors. 
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Therefore, I expect that the enhanced protection seen following immunization with Ad5PF is due 
to increased IL-17 driven neutrophil recruitment and opsonophagocytosis.  
Concluding Remarks 
 This work explores how Ad5 vectors can be used to generate protective immune 
responses to vaccine antigen. Ad vectors are ideal adjuvants because they potently activate both 
the innate and adaptive immune response, and vectors can be modified to encode vaccine 
antigens as transgenes. We generated Ad5 vectors expressing MRSA antigens and found that 
these vectors are able to induce both T and B cell responses to antigen. Specifically, Ad5 vectors 
induced both IL-17 and IFNγ responses to antigen that presumably come from antigen specific 
TH17 and TH1 cells. Immunization with a combination of these vectors, Ad5ClfA/Ad5SdrD, 
provided protection against cutaneous MRSA challenge. Current S. aureus vaccine strategies, 
mainly consisting of protein in Alum immunization, have proven unsuccessful in clinical trials. 
Importantly, Ad5ClfA/Ad5SdrD immunization provided greater protection than protein 
immunization, suggesting that Ad vectors represent a novel approach to generating a protective 
MRSA vaccine. 
 T cell responses, and TH17 produced IL-17 in particular, have been shown to be critical in 
mediating protection against cutaneous S. aureus infections. In order to augment Ad5 mediated 
protection, we generated modified Ad5 vectors displaying a peptide from the bacterial protein 
FliC that more potently induce IL-17 responses to transgene antigens. These vectors, Ad5PF, 
afforded greater protection from cutaneous infection with two different S. aureus strains than 
unmodified Ad5 vectors. Our studies using Ad5PF vectors suggest that it acts as a TH17 adjuvant 
and that Ad5PF vectors expressing S. aureus antigens would be ideal vaccine candidates.  
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 The experiments described in this work begin to explore the mechanism of Ad5 mediated 
protection against cutaneous MRSA infections. Our data show that protection correlates with 
increased expression of IL-17, which is known to stimulate production of neutrophil recruiting 
chemokines. Unsurprisingly, protection also correlated with expression of neutrophil recruiting 
chemokines CXCL1 and CXCL5. One mechanism by which phagocytic cells, including 
neutrophils, mediate S. aureus clearance is through opsonophagocytosis. Serum from 
Ad5ClfA/Ad5SdrD immunized mice contained antibodies with high binding affinity for FCγRs 
and mediated the greatest opsonophagocytosis of S. aureus compared to other immunization 
groups. From our data, we propose a possible model in which Ad5 vectors induce increased 
production of IL-17 and downstream chemokines leading to enhanced neutrophil recruitment to 
the site of infection. Upon recruitment to the site of infection, vaccine induced IgG2 antibodies 
against S. aureus surface proteins mediate opsonophagocytosis and clearance of S. aureus.
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